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Abstract
The c-Jun NH terminal kinase (JNK) group of kinases include ten
members that are created by alternative splicing of transcripts derived from Jnk1
Jnk2 and Jnk3 genes. The JNK1 and JNK2 protein kinases are ubiquitously
expressed while JNK3 is expressed in a limited number of tissues. The JNK
signaling pathway is implicated in multiple physiological processes including cell
transformation. There is growing evidence that JNK signaling is involved in
oncogenesis. Nevertheless, the role that JNK plays in malignant transformation
is still unclear. The aim of this thesis is to examine the role of JNK in malignant
transformation. For this purpose , I used the Bcr/Abl oncogene as a transforming
agent. Bcr/Abl is a leukemogenic oncogene that is created by reciprocal
translocation between chromosome 9 and 22. The translocation breakpoint is
variable and several different Bcr/Abl isoforms have been identified such as
Bcr/Ab1P185 and Bcr/AbIP210 , whose expression is associated with different types of
leukemia. Bcr/Abl activates the JNK signaling pathway in hematopoietic cells
and increases AP- 1 transcription activity. Furthermore, dominant negative
approaches demonstrate that inhibition of c-Jun or JNK prevents Bcr/ Abl-
induced cell transformation in vitro. These data implicate the JNK signaling
pathway in Bcr/Abl transformation although the role that JNK might have in this
process is unclear. Thus, I examined the importance of JNK signaling in Bcr/Abl-
vii
induced lymphoid or myeloid transformation. For this purpose I compared
Bcr/AbI P185- and Bcr/AbIP210- induced transformation of wild-type and JNK1-
deficient cells using three approaches: in vitro, in vivo and ex vivo. The results
obtained with the in vitro approach suggest that both Bcr/Ab1P185 and Bcr/AbIP210
require JNK activity to induce lymphoid transformation. While JNK1-deficiency
inhibits Bcr/Ab1P210 oncogenic potential in lymphoid cells both in vitro and in vivo
pharmacological inhibition of JNK activity (JNK1 and/or JNK2) blocked Bcr/Ab1P185
induced malignant proliferation in vitro. The differential requirement for JNK
observed in the two Bcr/Abl isoforms can be ascribed to the presence in
Bcr/AbIP210 of the Dbl domain which can activate the JNK pathway in vitro. In the
case of Bcr/AbIP210 , JNK1 is critical for the survival of the ex vivo derived
transformed Iymphoblasts upon growth factor removal. This result correlates
with the fact that mice reconstituted with Bcr/AbIP210 transformed Jnk1-
j- 
bone
marrow showed normal malignant lymphoid expansion in the bone marrow yet
they had reduced numbers of lymphoblast in the bloodstream and lacked
peripheral organ infiltration. Thus JNK1 is essential for the survival of the
transformed lymphoblast outside the bone marrow microenvironment in
Bcr/AbIP210 induced lymphoid leukemia. Interestingly, while JNK1 is essential for
lymphoid transformation , it is dispensable for the proliferation of transformed
myeloblasts.
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Taken together these results indicate that the JNK signaling pathway
plays an essential role in the survival of Bcr/AbIP210 Iymphoblasts and that JNK-
deficiency decreases the leukomogenic potential of Bcr/AbIP210 in vivo. Thus, cell
survival mediated by JNK may contribute to the pathogenesis of proliferative
diseases.
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Nomenclature
In this thesis I have used the following nomenclature:
Mouse genes are denoted in italics and first letter is capitalized (e.
g. 
Jnk1).
Human genes are in italics and all in upper case (e.
g. 
JNK1).
Proteins are denoted in regular font and the first letter is capitalized.
CHAPTER I
INTRODUCTION
The JNK/SAPK signal transduction pathway modulates the cell response
to external cues and has many biological actions including cell survival
apoptosis and tumorigenesis. The aim of this thesis is to investigate the role of
JNK in cell transformation.
1.1. JNK
The c-Jun N-terminal kinase (JNK), also known as stress-activated protein
kinase (SAPK), is a family of mitogen activated protein kinases (MAPKs). As the
name indicates, this group of MAPK is typically activated upon exposure of cells
to environmental stresses (UV , IR and genotoxic stress) and inflammatory
cytokines. This section gives an overview of the JNK/SAPK pathway and its role
in diverse cellular processes.
I. LA. The Signaling Pathway.
Like all MAPK pathways , JNK signaling includes a central "three-tiered"
signaling module (Fig. 1 A) in which the MAPKs are activated by phosphorylation
on specific threonine (Thr) and tyrosine (Tyr) residues within a conserved Thr-
Pro- Tyr motif located in the activation loop of their kinase domain. This
phosphorylation is carried out by a dual specificity (Ser/Thr and Tyr) kinase
known as MAPK kinase (MAPKK). These MAPKKs are, in turn, activated by
phosphorylation at serine (Ser)/threonine (Thr) residues located in their kinase
domain by upstream MAPKK kinases (MAPKKK). Some insight into the
biological role of the JNK pathway came with the characterization of the
components of this signaling module (reviewed in Davis, 2000; Kyriakis and
Avruch , 2001). At the MAPK level , the JNK protein kinases are encoded by three
genes: Jnk1 , Jnk2 and Jnk3 (Fig. 1 B). While Jnk1 and Jnk2 are ubiquitously
expressed, Jnk3 transcripts are found exclusively in heart, brain and testis. In
addition, each transcript can undergo two different types of alternative splicing
(Gupta et aI. , 1996). The first type of alternative splicing is common to all three
Jnk genes and involves the 3' coding region; this processing creates a 46 kD and
a 55 kD isoform. The second type of alternative splicing is observed only in Jnk1
and Jnk2 transcripts; this second alternative splicing occurs between two exons
within the kinase domain. The functional consequence of these splicing choices
is the generation of ten different isoforms of JNK. Although a difference in
substrate binding in vitro has been reported (Gupta et aI. , 1996), no dramatic
distinctions among JNK isoforms are observed in vivo. Despite the functional
complementation between the different Jnk genes, gene disruption studies
revealed that differential tissue distribution of the different isoforms might account
for tissue-specific defects. Thus, mice deficient in JNK1 or JNK2 have severe
defects in the differentiation of CD4 T helper cells into effector cells and this
defect may correlate with the pattern of JNK expression in murine T cells (Dong
et aI. , 2000; Dong et aI. , 1998; Yang et aI. , 1998).
The activity of all JNK isoforms is regulated by two competing
mechanisms: JNK can be inactivated by protein phosphatases (including
serine/threonine- , tyrosine- and dual specificity protein phosphatases) (Keyse,
2000) and activated by upstream MAPKK.
Inactive Active
I MAPKKK I 
MAPKKK I
Inactive
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I MAPKK I
APK
Ser Thr(E (f
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Fi$J.1 The MAPK signal transduction pathway. (A) The three tiered signallng module.
(B)Components of the Jnk signaling pathways.
There are two characterized MAPKK that phosphorylate all JNK isoforms:
MKK4 and MKK7 (Fig. 1 B). While MKK4 is also involved in the activation of the
p38 pathway in response to certain stimuli , MKK7 is a JNK-specific activator.
Genetic studies on MAPKK null cells revealed that MKK4 and MKK7 display
different activation patterns depending on the extracellular stimuli (Tournier et aI.,
2001; Tournier et aI. , 1997; Tournier et aI. , 1999; Yang et aI. , 1997a). Despite
this partial overlap in the activation pattern there is evidence that both of these
MAPKKs cooperate in the phosphorylation of JNK. Thus, MKK4 and MKK7
preferentially target JNK at Tyr and Thr respectively (Lawler et aI. , 1998). This
observation suggests a synergistic activation of JNK by these two MAPKKs.
The stress activated MAPKKs are regulated by Ser/Thr phosphorylation
within a conserved region of the activation loop. This phosphorylation is carried
out by a heterogeneous family of MAPKKKs (Fig. 1 B) (Davis, 2000; Kyriakis and
Avruch , 2001). There are several broad familes of MAPKKKs responsible for the
activation of the JNK signaling pathway: the MEK kinases (MEKK1-4), the mixed
lineage kinases (MLK1- , DLK and LZK), TGF- -activated kinase- 1 (Tak1),
Tumor progression locus-2 (TpI2) and the apoptosis stimulating kinases (ASK1-
2). Many of these MAP KKK were identified as JNK activators using transfection
assays (Fanger et aI. , 1997) but their role as physiological JNK activators in vivo
and their selectivity for the JNK pathway are still unclear. Some insight into the
in vivo function of some MAPKKKs comes from gene disruption studies (Davis
2000; Fanger et aI., 1997; Weston and Davis, 2002). Nevertheless, the
interpretation of these studies is particularly complex due to the inherent
redundancy among the different MAPKKKs and due to their promiscuity of
function. An additional level of complexity is determined by the upstream
signaling that activates MAPKKKs. In fact , the MAP KKK receive cellular inputs
from a highly diverse group of upstream kinases such as Ste20 homologs (PAK,
GCK, GLK and HPK) (Fanger et aI. , 1997) and the Rho family of GTPases (Rac1
and Cdc42) (Coso et aI., 1995; Minden et aI., 1995). Thus, the important role of
MAPKKK is the integration of these multiple cellular inputs into different MAPK
signaling modules.
Given the large number of signaling components in the JNK pathway
(especially at the MAP KKK level) a key issue for a stressed cell is the
achievement of rapid signal specificity. A clever solution is the organization of
the signaling components in discrete clusters through their interactions with
scaffolding proteins. Among the four groups of scaffolding proteins that provide
selective coordination of the JNK signaling pathway (Weston and Davis , 2002),
the best characterized is Jip (JNK interacting protein). The Jip family is
composed of three members (Jip- 1 -3), which differentially bind to specific
components of the JNK signaling module. In transfection studies , Jips faciltate
JNK activation stimulated by Mlk. This indicates that one functional role of these
scaffolds is the rapid and specific activation of the JNK pathway (Whitmarsh and
Davis, 1998). In contrast, overexpression of Jip1 alone can inhibit JNK activation
by extracellular stimuli (Dickens et aI. , 1997). This inhibition is probably due to
the disruption of the normal stochiometry of Jip and its effectors. In this situation
no single scaffold is associated with all the necessary components of the
- "
:1.
signaling cascade and the overexpressed Jip becomes a JNK inhibitor.
Interestingly, both Jip1 and Jip2 are able to bind to kinesin light chain in addition
to their functions as scaffolds for JNK signaling modules (Verhey et aI. , 2001;
Whitmarsh et aI. , 2001). This interaction may contribute to the subcellular
localization of JNK signaling components. Thus, Jip proteins may increase the
efficacy of the cell response by increasing the local kinase concentrations at
specific subcellular locations.
Because the activation of the JNK signaling module is critical for multiple
cellular responses, including stress- induced apoptosis, cell survival and
oncogenic transformation, the identification of potential JNK targets is essential.
The current list of potential targets includes transcription factors, tumor
suppressors and apoptosis regulating factors. The first characterized JNK target
is the c-Jun transcription factor, which provided a link between JNK signaling and
gene transcription (Kyriakis et aI. , 1994; Minden et aI. , 1994). JNK induced
transcriptional regulation is particularly important for cell survival and oncogenic
transformation , both of which usually rely on active transcription. The family of
transcription factors regulated by JNK phosphorylation has grown substantially
over the years and includes members of the ATF , Jun , NFAT , Myc and Ets
families. These factors are differentially regulated by JNK phosphorylation. The
first regulatory mechanism is the transcriptional activation of these factors by
JNK mediated phosphorylation of specific Ser/Thr residues present in their
,;:.
activation domains (Whitmarsh and Davis, 1996). Besides this common
regulatory mechanism the phosphorylation by JNK can also affect protein
stability. JNK phosphorylation of c-Jun increases its half- life , perhaps by
inhibiting its ubiquitin-mediated degradation , and thus effects its accumulation in
the cell (Musti et aI., 1997). In addition , JNK phosphorylation can inhibit
transcriptional activity of NFAT4 by inducing its nuclear exclusion (Chow et aI.
1997). Hence, JNK can regulate gene expression through different mechanisms:
by phosphorylating transcription factors, by affecting their stability or by affecting
their cellular localization.
Additional JNK targets are regulatory proteins involved in the apoptotic
stress response. Among these targets is the p53 tumor suppressor whose
expression levels are controlled by JNK phosphorylation. This regulation is at
both the transcription level (Schreiber et aI., 1999) and at the protein stability
level (Fuchs et aI. , 1998) where JNK regulates p53 ubiquitin mediated
degradation. Other potential JNK targets are the anti-apoptotic proteins such as
Mcl-1 and Bc12. Despite the fact that both Mcl- 1 and Bcl2 are JNK substrates 
vitro (Maundrell et aI. , 1997; Yamamoto et aI. , 1999) the relevance of this
phosphorylation in vivo is stil controversial. In the case of Mcl- , JNK mediated
phosphorylation is thought to inactivate Mcl-1 anti-apoptotic function (Inoshita et
aI. , 2002). In contrast , the biological effect of JNK phosphorylation of Bcl2 is
unclear. Conflicting reports have shown that JNK mediated phosphorylation of
,1,'".
the same residues in Bcl2 can have opposing effects in modulating the apoptotic
response (Breitschopf et aI. , 2000; Ita et aI. , 1997). Thus, further studies are
needed to establish if Bcl2 is a physiological substrate of JNK.
Recently, novel JNK targets were identified among the BH3-only proteins
(Donovan et aI. , 2002; Lei and Davis, 2003). The pro-apoptotic activity of the
BH3-only proteins Bad , Bim and Bmf is a result of JNK phosphorylation. In the
case of Bim and Bmf, JNK phosphorylation releases the proteins from the dynein
and myosin motor complexes. Once free, the factors are able to associate with
other members of the Bcl2 family such as Bax and Bak to trigger the stress-
induced apoptotic response (Lei and Davis, 2003).
The identification of additional targets will be critical for our understanding
of how JNK activity affects specific biological responses. Furthermore , the recent
characterization of a JNK inhibitory molecule (SP600125) will provide a useful
tool for the biochemical dissection of this signaling pathway. SP600125 is a drug
that potently inhibits JNK activity reversibly, in cultured cells (Bennett et aI.
2001). Since JNK may playa key role in different diseases such as cancer and
inflammation , this new inhibitor may represent a potential therapeutic agent in the
treatment of these pathological conditions.
.;-"-
I.I.B. Life or Death. a Stressful Choice.
Since the JNK pathway is activated mainly by stress, it is reasonable to
think that this activation has a role in the decision a damaged cell makes
between the choices of life versus death. Indeed there is evidence that JNK can
mediate both apoptosis and survival , which is important not only in response to
stressful conditions but also during development and tissue differentiation.
(1) Apoptosis
The involvement of JNK in the regulation of the apoptotic response was
first observed in neuronal cells. Withdrawal of nerve growth factor (NGF) or
other nutrients from differentiated neurons induces apoptosis and this response
requires activation of JNK and p38 with concomitant suppression of the Erk
survival pathway (Xia et aI. , 1995). Accordingly, constitutive activation of the
JNK pathway (by overexpression of the upstream MAP KKK, MEKK1) induces
apoptosis in neurons even in the presence of NGF. Conversely, expression of
dominant negative mutants of c-Jun prevents MEKK1 induced apoptosis
suggesting that this apoptotic response relies on JNK induced transcription. 
possible transcriptional target for JNK induced neuronal cell death is the pro-
apoptotic protein Fas- ligand (Fas-L). Indeed Fas-L expression is upregulated in
neurons upon NGF withdrawal in a JNK dependent fashion (Faris et aI. , 1998;
Kasibhatla et aI. , 1998; Le-Niculescu et aI. , 1999). Thus, a possible model for
;.t
stress- induced apoptosis in neuronal cells consists of JNK mediated up-
regulation of Fas-L with the newly expressed Fas-L binding to Fas-receptor and
triggering the apoptotic response. The involvement of JNK in neuronal cell death
is confirmed in studies conducted in animals with targeted disruption of the Jnk3
gene. These mice are defective in kainate- induced neuronal apoptosis
suggesting a role of JNK in brain response to stress by excitotoxins (Yang et aI.
1997b).
JNK contribution to neuronal apoptosis is not limited to the stress
response. Analysis of mice with combined ablation of JNK1 and JNK2 revealed
a potential role of JNK regulation of apoptosis during brain development. The
disruption of both Jnk1 and Jnk2 causes embryonic lethality with prominent
hindbrain exencephaly (Kuan et aI., 1999; Sabapathy et aI. , 1999). Careful
analysis of these embryos reveals opposite apoptotic defects in different brain
regions. In the lateral edges of the converging hindbrain there is a substantial
reduction of apoptotic degeneration , which accounts for the defect in cephalic
neurulation. Thus, in the hindbrain JNK1 and JNK2 are essential for
developmental apoptosis. In contrast , the forebrain regions of Jnk1-/- Jnk2-
double knock out mice show a dramatic increase in TUNEL positive cells , which
are indicative of apoptosis. Thus, JNK1 and JNK2 suppress cell death in the
forebrain region of the brain. These contrasting observations highlight a critical
issue in the analysis of JNK mediated signaling: the activation of the JNK
pathway may cause opposite biological outcomes depending on cellular context
(see later).
Some insight into the mechanism underlining JNK induced apoptosis
comes from the biochemical analysis of Jnk1-/- Jnk2-
/- 
mouse embryonic
fibroblasts (MEF). These cells are defective in apoptosis induced by specific
types of stress such as UV and anisomycin (Tournier et aI. , 2000). Subsequent
analysis showed that UV irradiated JNK null MEFs fail to induce mitochondria
membrane depolarization and cytochrome c release. These results suggest a
role of JNK in the regulation of the mitochondrial response to stress.
Furthermore , JNK mediated cytochrome c release requires the pro-apoptotic
factors Bax and Bak (Lei et aI. , 2002). Recently, it is been proposed that JNK
induces activation of BaxBak through the BH3-only proteins (Donovan et aI.
2002; Lei and Davis, 2003). Despite the identification of these new potential JNK
targets the mechanism that accounts for Bax/Bak activation and of the
mitochondrial apoptotic pathway is still unclear.
(2) Survival signaling
Although many studies clearly establish the role of the JNK pathway in cell
death , there is growing evidence that JNK can contribute to cell survival. The
strongest evidence supporting a role for JNK in cell survival comes from the
analysis of Jnk1-/- Jnk2-
/- 
embryos. As mentioned in the previous section , these
embryos exhibit increased apoptosis in the forebrain suggesting that JNK
provides a necessary survival signal in this specific brain region. Additional
evidence in support of JNK survival signaling derives from the characterization of
the TNFa response in Jnk1-/- Jnk2-
/- 
MEFs. These JNK null cells are more
sensitive than their wild-type counterparts to TNFa induced apoptosis (Lamb et
aI. , 2003). JNK survival signaling in response to TNFa treatment is dependent
on gene expression and it is mediated by the transcription factor JunD. 
potential target for JunD-dependent transcription in JNK survival signaling is the
inhibitor of caspases c- IAP2. Since TNFa- induced c- IAP2 expression is also
dependent on NF-KB activation the authors propose a model where the survival
signal in TNFa treated cells is triggered by the coordinated actions of JNK/JunD
and NF-KB. Thus , the presence of activated NF-KB translates TNFa- induced
JNK activation into a survival signal.
The importance of cellular context in JNK mediated survival signaling is
evident also in several antisense studies (Bast et aI. , 1999; Potapova et aI.
2000a; Potapova et aI. , 2000b). Here down-regulation of JNK2 expression
results in growth arrest and apoptosis only in tumor cell lines with mutated p53.
Thus in the absence of a functional p53 these tumor cells rely on JNK signaling
to promote survival.
A striking question that arises from all these studies is how JNK activation
can mediate opposite biological events such as apoptosis and cell survival.
There are several mechanisms that can explain this apparent paradox, none of
which are mutually exclusive:
First, the biological outcome of JNK activation may be dependent on
cellular context. In this case, the integration of multiple activated/suppressed
signaling pathways determines the choice between life and death. Two
examples of this mechanism are: the combined effects of the activation of JNK
and suppression of Erk pathway in NGF withdrawal induced apoptosis (Xia et aI.
1995) and the integration of JNK and NF-KB pathways in TNFa- induced survival
signaling (Lamb et aI. , 2003). In addition to this pathway integration , the cell
status may be important in the interpretation of a specific signal. For example, a
change in the p53 status of a cell may alter the outcome of the same JNK
mediated signal (Potapova et aI. , 2000b).
A second interesting mechanism is based on the correlation with the time
course of JNK activation for a specific biological response. In particular
sustained activation , but not transient activation , of JNK is associated with
apoptosis (Chen et aI. , 1996). Consistent with this model is the observation
TNFa induces only transient activation of JNK and this correlates with JNK
induced survival signaling.
A third possible mechanism is that different responses are mediated by
different JNK isoforms. Thus, heterogeneous tissue distribution of these
isoforms may account for the cell specific response to the same stimulus. In fact,
despite all JNK isoforms are largely interchangeable , the disruption of individual
Jnk genes gives rise to distinctive phenotypes (Conze et aI. , 2002; Dong et aI.
1998; Yang et aI. , 1998). These observations support the hypothesis that JNK
isoforms are heterogeneously expressed (either temporally or spatially) in
different tissues and that this distribution can determine the biological response
of the cells to a particular stimulus.
I.I.C. JNK and Cell Transformation
The process that leads to oncogenic transformation of normal cells
involves the alteration of important biological responses such as apoptosis and
cell survival. In fact the inhibition of apoptosis and the deregulation of growth
control are common mechanisms that allow oncogenes to transform cells (see
section LlI.D). Since JNK can regulate both apoptosis and cell survival it is not
surprising that multiple studies have implicated JNK signaling pathway and its
effectors in tumorigenesis. The first evidence of a role for JNK in cell
transformation came from studies conducted in c-jun deficient MEFs. The
transcription factor c-Jun is the best characterized effector of the JNK pathway.
Jun deficient MEFs exhibit several phenotypes and are strikingly resistant to
transformation by the Ras oncogene (Johnson et aI. , 1996). Similar results were
obtained using "knock- " mice expressing mutated c-Jun in which the JNK
phosphorylation sites (Ser63/73) are replaced by alanine residues (cJunAA).
cJunAA MEFs derived from these mice can be transformed by activated Ras 
vitro but are less tumorigenic in xenograft assays than wild type MEFs (Behrens
et aI. , 2000). This observation suggests that active phosphorylation of c-Jun by
JNK is required for efficient Ras transformation. Recently this hypothesis was
challenged by the observation that JNK-deficiency increases Ras oncogenic
potential. Thus, Ras transformed JNK null MEFs efficiently induced sub-
cutaneous and lung tumors when injected into nude mice (Kennedy et aI. , 2003).
In addition , JNK- deficiency increased the number and size of lung tumors in vivo
suggesting that JNK suppresses Ras oncogenic potential. The discrepancy
between the different Ras studies could be due to different cell context that might
influence the outcome of JNK signaling (see previous section).
Additional evidence suggests a role for the JNK pathway in Bcr/Abl
induced cell transformation. The Bcr/Abl oncogene constitutively activates JNK
and this activation has been proposed to be required for pre-B cell
transformation. In support of this hypothesis is the observation that expression of
dominant negative mutants of c-Jun efficiently blocks Bcr/Abl transformation 
vitro (Raitano et aI. , 1995). In accordance with this result, inhibition of JNK
signaling by overexpression of Jip1 abolishes Bcr/Abl induced pre-B cell
outgrowth in vitro (Dickens et aI. , 1997). Both of these studies provide indirect
evidence that JNK signaling pathway may contribute to malignant transformation
by Bcr/Abl therefore this oncogene is a suitable candidate to study the role of
JNK in cell transformation.
11. Bcr/Abl
LlI.A. The oncogene
The Bcr/Abl fusion protein is one of the first oncogenes found to be
associated with a specific malignant disease in humans (Nowell and Hungerford,
1960). This oncogene is generated in hematopoietic stem cells by reciprocal
translocation between chromosome 9 and chromosome 22 (t (9; 22)(q34; q11)
(Rowley, 1973). This reciprocal translocation gives rise to an abnormal
shortened chromosome 22 known as the Philadelphia chromosome (Ph). The
Philadelphia translocation is present in 90% of patients affected by Chronic
Myelogenous Leukemia (CML)(Pasternak et aI., 1998). The incidence of CML is
approximately 5 cases per 100,000 individuals per year worldwide and it is
slightly higher in males than in females. CML is a biphasic disease and it is
usually diagnosed in the initial "chronic" phase during which granulocytes
increase in number 10- to 100- fold in the blood (reviewed in Sawyers , 1999).
Despite this leukocytosis, normal hematopoiesis still coexists with the leukemic
clone. The chronic phase lasts typically 2-6 years and suddenly transforms into
a more aggressive phase usually described as "acute" or "blast crisis . At this
stage , immature cells appear and normal hematopoiesis is overcome by the
malignant clone. Blast crisis patients exhibit additional chromosomal
abnormalities such as trisomies 8 and 19 and isochromosome 17. These
rearrangements have prognostic relevance in the identification of the shift to the
more aggressive phase. The median survival of patients in this stage is only
about 1 .5 years.
Two genes are engaged in the creation of the Bcr/Abl fusion protein: ABL
on chromosome 22 and BCR on chromosome 9. Insights on the transformation
events leading to the development of CML come from the characterization of
these genes.
The BCR (breakpoint Qluster region) gene encodes for a 160kD
cytoplasmic protein that is ubiquitously expressed. The physiological role of the
Bcr protein is not yet clear. Bcrknock-out mice do not have any obvious external
phenotype and show normal hematopoiesis and viability. However , when
challenged with endotoxin (Voncken et aI. , 1995) these mice develop severe
septic shock attributed to an increased neutrophilic oxidative burst. The absence
of a clear hematopoietic phenotype suggests an inherited redundancy in the cell-
signaling pathway.
The translocation partner for Bcr in the Philadelphia chromosome is the
ABL gene. This gene encodes a non-receptor tyrosine kinase , which shares
considerable homology with the Abl (Abelson murine leukemia virus)
oncogene. As is the case with the Bcr gene, the function of ABL kinase is poorly
understood. Some insight comes from knock-out studies where the Abl gene
was either truncated or completely ablated (Schwartzberg et aI. , 1991;
Tybulewicz et aI. , 1991). In both cases the Abl-
/- 
mice showed reduced survival
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and only some exhibited a 10- 30-fold reduction in the number of B- and T - cells.
It is unclear whether the observed lymphopenia is a direct effect of the disruption
of the Abl gene or a secondary effect due to an increase in corticosteroids levels.
Further analysis of Abl null mice has also revealed a defect in osteoblast
maturation (Li et aI. , 2000). The osteopororotic phenotype displays a reduction in
the rate of bone deposition and is present in approximately 50% of the Abl-
homozygote mice (Li et aI., 2000). The incomplete penetrance of all Abl-
phenotypes could be ascribed to the presence of a compensatory kinase with
redundant function. One potential candidate that could compensate Abl function
in vivo is the Abl-related gene (Arg) kinase (Kruh et aI. , 1986). Both Arg and Abl
kinases exhibit extensive conservation in sequence and architecture. Despite
this high degree of identity, gene disruption studies suggest that these tyrosine
kinases have different functions in vivo. In fact, Arg deficient mice are born
normal and do not exhibit the defects observed in Abl null mice (Koleske et aI.
1998) suggesting that Arg cannot compensate for Abl deficiency. In addition , the
combined disruption of Abl and Arg genes causes embryonic death associated
with defects in neural tube closure (Koleske et aI., 1998) indicating that Arg
function is necessary to sustain the development of Abl- deficient mice.
In vitro studies that describe the Abl kinase as a cell cycle regulator are
controversial. Some studies have shown that a fraction of the Abl nuclear pool is
associated with the retinoblastoma protein (Rb) in cells in G1 (Wang, 1993;
Welch and Wang, 1993). This binding inhibits the Abl kinase activity during this
phase. Upon phosphorylation of the Rb protein by cyclinD-cdk4/6 the Abl kinase
is released and consequently activated in S phase. This activation is thought to
contribute to the stimulation of the S-phase genes through phosphorylation of the
terminal domain of RNA polymerase II. Thus, this study envisions the Abl
kinase as a growth-promoting factor. An opposite role for the Abl kinase is
described in transfection studies (Van Etten , 1999) where Abl induces G1 growth
arrest and subsequent apoptosis. This function of the Abl kinase is dependant
on its SH2 domain and its association with p53 and Rb.
The Abl kinase is also involved in the DNA damage response (Van Etten
1999; Wang, 2000). Ionizing radiation and genotoxic agents such as mitomycin
C activate the kinase activity of nuclear c-Abl. This activation can occur either by
direct phosphorylation of Abl by the ataxia telangectasia-mutated (A TM) kinase
(Baskaran et aI. , 1997; Shafman et aI. , 1997) or indirectly by free radical
induced dissociation of the Abl kinase from its inhibitor Pag/MSP23 (Wen and
Van Etten , 1997). Upon activation c-Abl phosphorylates multiple substrates
including DNA-PK (Kharbanda et aI. , 1997), Rad 51 (Yuan et aI. , 1998), SHPTP1
(Kharbanda et aI. , 1996). Although these interactions suggest a role of the Abl
kinase in the regulation of the DNA double-strand break repair, such a role is not
evident in Abl-
/- 
fibroblasts. These cells do not display defects in the DNA repair
pathways or in the regulation of the G1-S checkpoint and are slightly more
radioresistant than their Abl+/+ counterparts (Yuan et aI. , 1997). It is possible
that failure to detect these defects is due to the intrinsic redundancy of the
pathway. Recent studies on Abl deficient mice (Gong et aI. , 1999) and chick
cells (Takao et aI. , 2000) support an alternative role for c-Abl kinase in the DNA
damage response. Both studies provide evidence for a role of c-Abl tyrosine
kinase in the activation of apoptosis by DNA damage. One mechanism
underlying c-Abl induced cell death is through the regulation of p73 expression
(Gong et aI. , 1999). p73 belongs to the family of p53 transcription factors and is
thought to have a role in the regulation of apoptosis (Levrero et aI. , 1999).
Indeed , ectopic expression of p73 (like p53) can induce apoptosis (Levrero et aI.
1999) indicating that p73 protein level is critical for the induction of apoptosis.
Interestingly, the accumulation of p73 following exposure to genotoxic stress is c-
Abl dependant (Gong et aI. , 1999). This accumulation is due to an increase in
the half- life of the p73 protein (Gong et aI. , 1999) and is perhaps mediated by
direct phosphorylation of p73 by the c-Abl kinase (Agami et aI. , 1999).
The Philadelphia translocation between BCR and ABL gives rise to two
hybrid genes: Bcr/Abl on chromosome 22 and Abl/Bcr on chromosome 9q+.
Only the Bcr/Abl fusion protein is shown to be necessary and sufficient for
malignant transformation in vitro as well as in vivo (Daley and Baltimore, 1988;
Daley et aI. , 1990; Heisterkamp et aI. , 1990; Kellher et aI. , 1990) while the
possible role of the Abl/Bcr remains elusive.
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Fig.2 Genomic structure of the A8L and 8CR gene (top). The 300Kb se ment at the 5' end ofBcr/Abl isoforms generated by translocation involving the three
breakpoint regions in the BCR gene (bottom). (Modified from Melo(1996)). the gene. This segment
includes the two alternative first exons of the ABL gene. Thus, the fusion protein
may contain exons Ib and la, exon la alone or neither one. Interestingly, the
Bcr/Abl transcript never includes ABL exon I despite the genomic arrangement of
the fusion gene. All described Bcr/Abl mRNAs consist of BCR sequences fused
to ABL exon a2 (Melo, 1996). While the ABL contribution to the fusion oncogene
is usually invariable , the translocation of different portions of the BCR gene
determines the formation of Bcr/Abl isoforms. There are three characterized
breakpoint regions in the BCR gene: the major (M-bcr), the minor (m-bcr) and the
micro (Wbcr) breakpoint cluster (Fig. 2). Each one of these breakpoint clusters
and its related Bcr/Abl isoform is associated with a specific type of leukemia.
Breakage within the bcrgenerates an 8. kb transcript that encodes for a 210
kD (Bcr/AbIP210) fusion protein which is found in 95% of patients with Chronic
Myelogenous Leukemia (CML) and approximately one third of patients with
Acute Lymphoid Leukemia (ALL). The majority of ALL patients and rare cases of
CML patients express a smaller 185kD Bcr/Abl isoform (Bcr/AbIP185) as a result of
breakage in the bcr region. In 1990, Saglio et al. described a 230kD Bcr/Abl
isoform (Bcr/AbIP230) found in patients with Chronic Neutrophilic Leukemia (CNL)
(Saglio et aI. , 1990). The breakpoint responsible for the creation of the largest
Bcr/Abl isoform is the 
wbcr located at the 3 end of the BCR gene.
In addition to these well-characterized isoforms other "unusual" transcripts
are observed in which the chromosomal breakpoint occurs either in introns
outside the known bcr breakpoint clusters or within BCR exons or downstream
the ABL exon a2. Interestingly, many of these atypical Bcr/Abl fusion genes can
be detected by RT -PCR in leukocytes of 69% of normal individuals (Bose et aI.
1998) indicating that the translocation is not , in itself , sufficient for malignant
transformation.
LlI.B. Structure of the Bcr/Abl fusion protein
Both the Bcr and the Abl proteins have multiple functional domains that
contribute to different transforming events induced by Bcr/Abl. These aspects
include the resistance to apoptosis , growth factor independence and alterations
of cell-cell and cell-matrix interactions. In addition , since Bcr/Abl isoforms differ
only in the Bcr portion of the fusion oncogene , the structural characterization of
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the different Bcr domains may be helpful in our understanding of the oncogenic
potential of these isoforms.
(1) BCR
The BCR gene encodes for 160 kD cytoplasmic protein that contains
several distinct domains (Fig. 3). The N-terminal region is particularly important
since it is the only Bcr peptide that is retained in all three Bcr/Abl isoforms
(Bcr/AbIP185 , Bcr/AbIP210 and Bcr/AbIP230). This 426aa region includes: a coiled coil
Bcr
domain (or
:..
p230
p210
oligomerization domain),
p185 a serine-threonine kinase
domain containing an
NH - 
. SerinefTreonine
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Fig.3 Domain structure of Bcr. Arrows indicate the Bcr portions
comprised in the different Bcr/Abl isoforms.
(Modified from Barnes and Melo (2002)).
Src homology 2 (SH2)-
binding region.
The coiled coil region (Fig. 3) consists of a heptad repeat typical of coiled coil
amphiphatic alpha elices, which suggests a role in the oligomerization of the Bcr
protein. Further studies established that both the Bcr protein and the Bcr/Abl
fusions form oligomers in vivo (McWhirter et aI. , 1993). In the case of Bcr, the
crystal structure revealed the formation of a homotetramer (Zhao et aI. , 2002).
Based on these findings the authors propose a model for the activation of the Abl
kinase in Bcr/Abl based on the tetramerization of the fusion protein. The N-
terminal coiled coil domain is both essential and suffcient to activate the
oncogenic potential of Abl by inducing CML- like disease in mice (Zhang et aI.
2001 a). Deletion of the coiled coil region (i1CC) impairs the ability of Bcr/Abl to
induce myeloid leukemia in vivo. Interestingly, the concomitant deletion of the
Abl SH3 (i1SH3) domain rescues the ability to induce transformation in
transplanted mice. This result suggests that the coiled coil region alleviates the
inhibitory effect of the Abl SH3 domain.
The serine -threonine kinase (Fig. 3) domain has been shown to
autophosphorylate itself as well as Bap-1 (Bcr associated protein 1) a member of
the 14- 3 family of proteins (Reuther et aI. , 1994). Since 14- 3 proteins are
important in the regulation of the cell cycle in yeast the authors speculate that the
association and consequent phosphorylation of Bap-1 in Bcr/Abl cells may be
relevant as a mitogenic signal provided by this oncogene in transformed cells
(Reuther et aI. , 1994).
In addition , the serine/threonine kinase domain contains a very important
tyrosine residue (Tyr 177) (Fig. 3). This residue is key to the activation of the
Ras signaling pathway by Bcr/Abl. Upon phosphorylation , this residue binds to
Grb2 adapter molecule through its SH2 domain. The SH3 domain of Grb2 binds
to proline-rich motifs on the guanine nucleotide releasing factor son-of-sevenless
(Sos), which activates Ras by stimulating GTP binding. Activation of Ras leads
to the activation of the mitogen-activated protein kinase (MAPK) and other
signaling pathways (see later). Mutation of this single residue in Bcr/Abl impairs
its ability to induce a myeloprolierative disease in mice although it still retains the
ability to induce lymphoid leukemia (Million and Van Etten , 2000). The residual
oncogenic activity observed is perhaps due to the ability of the Tyr177F mutant to
still activate the Ras pathway through the activation of either Shc (Gaga et aI.
1995) or CrkL (Nosaka et aI. , 1999b; Senechal et aI. , 1996). Recently, a novel
regulatory mechanism for Bcr/Abl was demonstrated which involved the
phosphorylation of Grb2 on Tyr209 (Li et aI. , 2001a). This modification directly
inhibits the binding of Sos by the Grb2 C-terminal SH3 domain. Expression of
mutated Grb2 (Y209F) enhances the transformation ability of Bcr/Abl in vitro
suggesting that the phosphorylation of Grb2 at this site exerts a negative
regulatory role in Bcr/Abl - induced transformation.
Finally, the SH2-binding region (Fig. 3) within the N-terminal region of Bcr
consists of two areas that are particularly rich in serine and threonine residues.
Interestingly, the phosphorylated Ser/Thr residues become unusual binding
partners with SH2 domains of other proteins , one of which is the Abl portion of
Bcr/Abl. An intriguing hypothesis is that intra- or inter- molecular binding
between these two regions might lead to the deregulation of Bcr/Abl tyrosine
kinase activity. Supporting this model are deletion studies showing that the
Ser/Thr regions in the SH2-binding domain of Bcr are essential for Bcr/Abl
induced transformation of rat fibroblasts (Pendergast et aI. , 1991).
The central region (Fig.3) of the Bcr protein is present in the two largest
Bcr/Abl isoforms. This area shares considerable homology with the guanine-
nucleotide exchange factor (GEF) for human CDC42: the Dbl proto-oncogene.
These factors activate guanine nucleotide binding proteins by stimulating the
exchange of guanosine triphosphate (GTP) for guanosine diphosphate (GDP).
Domain swap analysis showed that the Dbl domain is important in inducing
growth-factor independence in vitro (Kin et aI. , 2001) but the exact role of this
domain is yet to be discovered.
(2) ABL
Unlike the case for Bcr, the Abl portion is constant in all Bcr/Abl isoforms
(Fig. 4). The translocation breakpoint excludes the N-terminal cap that is
encoded by two alternative exons (Ia and Ib). Beyond the breakpoint, the N-
terminal region included in the oncogene unfolds different Src homology
domains: SH1 containing the Abl tyrosine kinase, SH2 and SH3 which are non-
catalytic and function as binding sites for many other signaling proteins (see
later). Bcr/Abl is a constitutively active tyrosine kinase and its activity is
necessary yet not sufficient for its transforming ability. In c-Abl , negative
regulation of the tyrosine kinase is achieved through its SH3 domain (Fig. 4).
There are two possible regulatory mechanisms involving the SH3 domain that
lead to the inhibition of c-Abl kinase activity. The first mechanism is based on the
interaction of c-Abl SH3 domain with a cellular inhibitor. Several candidate
inhibitors (such as Abi- , Abi-2 and Pag/MSP23) that bind to c-Abl SH3 domain
have been identified (Van Etten , 1999) but their physiological role as regulators
of c-Abl kinase activity is still unclear. The second mechanism envisions the
formation of an intramolecular interaction involving the SH3 domain and the
linker region between the SH2 and the catalytic domain (Pluk et aI. , 2002).
Interestingly, the N-terminal cap of c-Abl encoded by two alternative exons (Ia or
Ib) is thought to be critical for this intramolecular regulation (Pluk et aI. , 2002).
Thus, the deletion of this N-terminal cap in the Bcr/Abl translocation could
contribute to the deregulation of its tyrosine kinase activity.
In addition , deletion of the SH3 domain or its substitution with gag viral
sequence (as in the case of v-Abl) activates c-Abl transforming ability in vivo
(Van Etten , 1999). In contrast , Bcr/Abl 8SH3 mutants either have a milder form
of the disease (Skorski et aI. , 1998) or develop a CML- like leukemia with a slight
delay (Gross et aI. , 1999b). These results suggest that the presence of SH3
domain enhances (rather than inhibits) the oncogenic potential of Bcr/Abl. 
possible role for the Abl SH3 domain in the Bcr/Abl fusion is to regulate the
adhesion and motility of the leukemic cells. Cells transformed with Bcr/AbI8SH3
have a reduced ability to adhere to stromal layers and to invade bone marrow
and spleen (Skorski et aI. , 1998). The impaired adhesion and invasion is
ascribed to defective cell-cell and cell-matrix interactions rather than to reduced
survival of the
Abl transformed cells.
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Fig.4 Domain structure of Abl. Arrow indicate the Abl portion
comprised in all Bcr/Abl isoforms.
(Modified from Barnes and Melo (2002)).
region: the SH2
domain (Fig. 4). The
role of this domain in Bcr/Abl induced cell transformation is rather controversial.
Initial studies using a SH2 deletion mutant showed a reduction in the extent of
myeloid infiltration in the peripheral organs of transplanted mice (Skorski et aI.
1997). At a molecular level , the Bcr/AbI8SH2 mutant seemed to be impaired in
the activation of the Pl3-Kinase and of the downstream serine/threonine kinase
Akt. In accordance, coexpression of an Akt constitutively active mutant restores
the ability of the SH2 deletion mutant to induce leukemia in vivo. Subsequent
studies (Roumiantsev et aI. , 2001; Zhang et aI. , 2001 b) confirmed the defect of
the Bcr/Abl SH2 mutant to induce CML- like disease but observed normal
induction of the PI-3K /Akt pathway with this mutant. The authors ascribe the
decrease efficiency of induction of CML disease to a dramatic reduction in the
intrinsic tyrosine kinase activity of Bcr/Abl proteins. This controversy highlighted
one of the fundamental challenges in Bcr/Abl research: the requirement for
specific domains for Bcr/Abl- induced transformation is typically cell type- or
context- dependent. Up to now it is not clear which experimental model system
should be used in order to evaluate Bcr/Abl domain function and have
observations relevant to the development of CML in humans.
The C-terminal region of Abl is characterized by three nuclear localization
signals (NLS) as well as one nuclear-export signal (NES) (Fig. 4). In the case of
Abl , the balance of the opposing effects of these two regions creates a cellular
gradient of the Abl kinase with a higher concentration in the nucleus. This
gradient can be disrupted by the use of nuclear-export inhibitory drugs such as
leptomycin B (Vigneri and Wang, 2001). Despite the presence of the same NLS
and NES regions in all Bcr/Abl fusions, the cellular distribution of the oncoprotein
is strictly cytoplasmic. Nevertheless, inhibition of Bcr/Abl tyrosine kinase activity
in the presence of leptomycin B induces Bcr/Abl nuclear import. Once trapped in
the nucleus the release of kinase inhibition induces an immediate apoptotic
response (Vigneri and Wang, 2001). This may explain the tight cytoplasmic
localization of the oncogene. For this purpose , the C- terminus Actin-binding
domain (Fig. 4) provides an important cytoplasmic anchoring domain. This
domain can bind to both monomeric and filamentous actin and it is thought that
the Abl kinase can influence and be influenced by local changes of the
cytoskeleton structure. The relationship between abl kinase activity and
cytoskeleton is underlined by the observation that the Abl cytoplasmic pool
relocates into focal adhesion once cells become exposed to fibronectin (Van
Etten , 1999). The disruption of this integrin signaling is one of the many affected
pathways in the Bcr/Abl fusion oncogene.
LlI.C. Activated signaling pathway by Bcr/Abl
The functional consequence of the fusion of the Bcr sequence to Abl is the
conversion to a constitutive active tyrosine kinase and its localization to the
cytoplasm. Here, the new deregulated kinase is exposed to a variety of new
potential substrates and activates different signaling pathways which contribute
to the cell transformation (Fig. 5). This section provides an overview of the
signaling pathways activated in Bcr/Abl transformed cells.
Despite the identification of these newly activated signaling pathways it is
difficult to link any specific signaling event to a specific biological effect due to the
redundancy of many of the activated pathways. Nevertheless, the understanding
of the molecular processes that stem from the deregulation of Bcr/Abl is
important for future development of a therapeutic strategy.
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Fig.S Bcr/Abl activated signalling pathways.
Ras signaling is one of the first deregulated pathways found in Bcr/Abl
transformed cells. The key to the identification of Ras activation was the finding
of the Grb2/Sos association at Tyr177 on Bcr/Abl (Fig 5)(Pendergast et aI.
1993). The formation of this complex stimulates the conversion of the inactive
GDP-bound form of Ras to the active GTP-bound state. Later studies
established that Bcr/Abl-nduced activation of Ras also could be achieved
through two other adapter molecules: SHC and CrkL (Gaga et aI. , 1995; Nosaka
et aI., 1999b; Senechal et aI. , 1996). Both these adapters are known Bcr/Abl
substrates and associate with the SH2 (Shc) and SH3 (CrkL) domains
respectively. Interestingly, the CRKL adapter protein is one of the most
prominent tyrosine phosphorylated Bcr/Abl substrates found in CML patients
(Oda et aI. , 1994; ten Hoeve et aI. , 1994). This observation suggests that CrkL
plays a critical role in Bcr/Abl induced transformation (de Jong et aI., 1995;
Heaney et aI. , 1997; Hemmeryckx et aI. , 2001; Kardinal et aI. , 2000; Kolibaba et
aI. , 1999; Oda et aI. , 1994; Senechal et aI. , 1996; Tari et aI. , 1997; ten Hoeve et
aI. , 1994). In fact, inhibition of complexes mediated by CrkL SH3 domain can
block proliferation of CML cell lines (Kardinal et aI. , 2000). In contrast, transgenic
expression of CrkL accelerates the onset of Bcr/Ab1P185 induced disease
(Hemmeryckx et aI. , 2001). Despite the critical role of CrkL in Bcr/Abl signaling,
CrkL is not required for Bcr/Ab1P185 induced leukomogenesis (Hemmeryckx et aI.
2002). Since Bcr/Abl activates Ras through multiple pathways , it is possible that
these redundant pathways can compensate for CrkL deficiency.
Two different MAPK are activated through Ras in Bcr/Abl transformed
cells: the extracellular signal-related kinase (Erk) and the Jun NH terminal
kinase (JNK). Activation of Erk is mediated by Raf activation of the
serine/threonine kinases Mek1/Mek2 (Fig. 5) while in the case of JNK the signal
is transduced by the germinal center kinase -related (GCKR) (Shiet aI. , 2000;
Shi et aI. , 1999). The functional importance of Ras in Bcr/Abl induced cell
transformation was demonstrated by dominant negative studies (Sawyers et aI.
1995). Coexpression of Bcr/Abl with either GAP or dominant negative Ras
hinders its oncogenic potential while coexpression of c- Ras accelerates its
transforming ability (Sawyers et aI. , 1995). Ras has a central role in mediating a
growth-stimulatory signal in different human leukemias. Deregulation of the Ras
pathway through specific activating mutations is observed with high frequency in
patients with acute myeloid leukemia (AML) or Ph-negative CML (which thereby
lack the Bcr/Ablfusion protein) while Ras mutations are noticeably absent in Ph+
CML patients (Cogswell et aI. , 1989; Watzinger et aI. , 1994). This apparent
paradox could be explained by the fact that in Bcr/Abl expressing leukemias the
Ras pathway is constitutively activated, consequently further activating mutations
may not be required.
(2) JNK
Bcr/Abl transformed hematopoietic cells show increased JNK activity and
substantial activation of jun-responsive promoters (Raitano et aI. , 1995).
Interestingly, among the MAPK pathways Bcr/Abl preferentially activates JNK
and this activation is Ras-dependent. In fact, use of dominant negative Ras
mutants block Bcr/Abl induced JNK activation (Shi et aI. , 1999). The link
connecting Bcr/Abl , Ras and JNK is thought to be the Germinal Center Kinase
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Related (GCKR) (Fig. 5). GCKR kinase associates and is activated by Bcr/Abl in
a Ras-dependent manner. Inhibition of the GCRK activity by either a dominant
negative mutant or by antisense blocks Bcr/Abl induced activation of JNK (Shi et
aI. , 1999). These results identify GRCK kinase as the transducer of Bcr/Abl
signaling to JNK. The main downstream effector of JNK is the c-Jun transcription
factor. JNK phosphorylation of c-Jun at Ser63 and Ser73 leads to the increase of
jun-responsive gene transcription including the c-jun gene itself. c-Jun-mediated
transcription is essential for Bcr/Abl cell transformation. Expression of dominant
negative mutants of c-Jun can inhibit Bcr/Abl oncogenic potential in vitro (Raitano
et aI. , 1995). Interestingly, substantial JNK activity and subsequent Ap-
dependent gene transcription is observed in blast cells derived from patients with
acute myeloid leukemia (Burgess et aI. , 1998). In addition , there is an intriguing
correlation between constitutive JNK activity and patients that show either
relapse or secondary leukemia whereas young patients with de novo acute
leukemia lack JNK activity and fail to express c-Jun protein (Burgess et aI. , 1998;
Cripe et aI. , 2002). Very high levels of JNK activity are especially found in acute
myeloid leukemia patients that are refractory to chemotherapy. This observation
supports the hypothesis that JNK might induce resistance to chemical agents by
c-jun-dependent transcriptional upregulation of multidrug resistance genes such
as MDR1 (Cripe et aI. , 2002). These findings are fundamental for the
development of therapeutic strategies in AML patients that fail conventional
treatment.
(3) Jak/Stat
Many studies have reported the phosphorylation of the signal transducer
and activator of transcription (STAT) family in CML cell lines. The STAT
transcription factors are important mediators of cytokine and growth factor
signaling. Activation of these transcription factors is achieved through tyrosine
phosphorylation and is usually mediated by the Janus kinases (JAKs). STATs
are activated in Bcr/Abl expressing cell lines. In these lines there is substantial
phosphorylation of ST A T5A and ST A T5B and modest activation of ST A T1 ,
STAT3 and STAT6 (liaria and Van Etten , 1996; Nieborowska-Skorska et aI.
1999; Shuai et aI. , 1996). Interestingly, the phosphorylation of STAT6 is
detected in cell lines transformed with either v-Abl or Bcr/Ab1P185 and not with
Bcr/AbIP210 (liaria and Van Etten , 1996). Since both v-Abl and Bcr/Ab1P185 induce
primarily lymphoid leukemias , ST A T6 phosphorylation might be a hallmark for
lymphoid transformation.
Although JAK2 is activated in Bcr/Abl expressing cell lines, the activation
of STAT5 is JAK- independent (Carlesso et aI. , 1996; Chai et aI. , 1997; lIaria and
Van Etten , 1996; Xie et aI. , 2001). Several studies identified the involvement of
Hck as the tyrosine kinase that couples Bcr/Abl to STAT5 activation in myeloid
cells (Fig. 5) (Klejman et aI., 2002; Lionberger et aI. , 2000). Hck is recruited to
the SH2 and SH3 domains of Bcr/Abl , becomes activated and directly
phosphorylate ST A T5 on Tyr699 (Klejman et aI. , 2002). Inhibition of ST A T5
activation by expression of a truncation mutant lacking the transcriptional
activation domain (L\STAT5) reduces cell viability in Bcr/Abl+ cell lines (Gesbert
and Griffin , 2000). The reduced viability is due to increased apoptosis rather
than cell cycle blockage. On the other hand , expression of a constitutively active
STAT5 mutant (STAT51 *6) results in growth factor- independent proliferation and
enhanced viability. STAT5- induced cell survival is mediated by transcriptional
upregulation of anti-apoptotic BcIX . Again , dominant negative L\STAT5 mutant
reduces BclX levels in Bcr/Abl+ cell lines (Horita et aI. , 2000) while STAT51 *
upregulates them.
The importance of STAT5-mediated cell survival in Bcr/Abl transformation
depicted by these in vitro studies has been challenged by recent work carried out
in STAT5A1B-deficient mice (Sexl et aI. , 2000). Results from this study show that
Bcr/Abl can induce myeloproliferative disease in STAT5A1B- deficient mice. This
indicates that STAT5A1B signaling is not essential or necessary for Bcr/Abl-
induced transformation. In addition , the authors found no expression of STAT5-
dependent genes in cell lines derived from tumors from ST A T5A1B-deficient mice
indicating that no redundant pathway is compensating for the absence of STAT5
signaling.
(4) PI3 Kinase
PI3 Kinases (PI3K) are pleiotropic regulators of many biological function
including apoptosis, proliferation and integrin activation. Bcr/Abl constitutively
activates PI-3 Kinase through multiple pathways. The first identified pathway
involved the formation of a multimeric complex with the regulatory subunit of the
PI3K (p85), p120Cbl , Crk and CrkL (Fig. 5) (Sattler et aI. , 1996). The association
of the regulatory p85 subunit with the activated tyrosine kinase activates the
p110 catalytic subunit of the Pl3-kinase and its downstream effectors. Recently,
a second model was described in which Bcr/Abl induced PI3K activation through
the recruitment of the scaffolding adaptor Gab2 (Sattler et aI. , 2002). The
recruitment is mediated by the formation of a Grb2/Gab2 complex that associates
with Bcr/Abl at Tyr177. Since Tyr177 is known to be important in the activation of
Ras signaling pathway (see previous section), the authors speculate that Gab2
could be responsible for the regulation of the Ras/Erk pathway.
The downstream effector that transduces Pl3K-signal in Bcr/Abl
transformed cells is the serine/threonine kinase Akt (Fig.5). Pl3K-mediated
activation of Akt is essential for Bcr/Abl-nduced leukomogenesis: a dominant
negative Akt mutant or the PI3K inhibitory drug wortmannin both inhibit Bcr/Abl-
dependent transformation in vitro and in vivo (Skorski et aI. , 1997). In CML cells
activated Akt has multiple downstream signaling targets, which contribute to
different aspects of cell transformation. Among these targets there is a key cell
/ .
cycle regulator p27KiP1 . p27KiP1 is an inhibitor of the cell cycle kinase cdk2.
Binding of p27KiP1 to the cdk2/cyclinE complex prevents the phosphorylation of
effectors (such as Rb) essential for entry in S phase. In Bcr/Abl expressing cell
lines, Akt-mediated phosphorylation of p27KiP1 induces its downregulation
perhaps through proteasome-mediated degradation (Gesbert et aI. , 2000). The
resulting low levels of p27KiP1 lead to an accelerated entry to the S phase
suggesting that the PI-3K/Akt pathway mediates one of Bcr/Abl mitogenic
signals.
Another key substrate of the PI-3K/Akt pathway is the pro-apoptotic
protein Bad. Bad induces apoptosis by sequestering Bcl2 and BclX anti-
apoptotic factors. Bad phosphorylation by Akt induces its association with
cytoplasmic 14- 3 proteins, which prevents the formation of the inactivating
complex with Bcl2 and BcIX . Bad phosphorylation by PI-3K/Akt is an important
survival signal in Bcr/Abl transformed cells (Neshat et aI. , 2000). Interestingly,
other pro-apototic factors such as Bim are downregulated by PI-3K/Akt pathway
in CML cell lines. In this case, the regulation is thought to be mediated by Akt-
mediated repression of FKHR-L 1 transcriptional activity (Komatsu et aI. , 2002).
Taken together these studies provide evidence that the PI-3K/Akt pathway
mediates many aspects of Bcr/Abl induced cell transformation including inhibition
of apoptosis and mitogenic stimulation of the transformed cells.
1. I. D. Mechanisms of transformation
Several lines of evidence indicate that tumorigenesis is a multistep
process. A normal cell undergoes essential alterations of important cellular
functions that collectively lead to malignant transformation. Like many other
oncogenes, Bcr/Abl accelerates the rate of accumulation of these physiological
alterations by deregulating multiple cellular processes through the activation of
multiple signaling pathways. Each signaling pathway activated by Bcr/Abl
contributes to one or more of these cellular alterations. These important cellular
alterations include: growth factor independence, inhibition of apoptosis, mitogenic
stimulus, altered adhesion and tissue invasion , limitless replicative potential and
genome instability.
(1) Growth factor independence
Proliferation and differentiation of hematopoietic cells is tightly regulated
by several growth factors (GF) and cytokines such as interleukin 3, oncostatin M
and GM-CSF. These factors activate specific signaling pathways through their
association with cell surface receptors. While normal cells depend on the
activation of these pathways for their survival , Bcr/Abl transformed cells can
survive in the absence of these factors. In transformed cells different strategies
can be used to achieve growth factor independence including the autocrine
production of the growth factors and the aberrant activation of cytokine signal
transduction pathways.
Many cancer cells acquire the ability to produce the growth factors to
which they are responsive. This self-supporting production creates a positive
feedback signaling loop often described as autocrine stimulation. Bcr/Abl
expressing myeloid cell lines synthesize granulocyte-macrophage colony-
stimulating factor (GM-CSF) and/or interleukin 3 (IL-3). The conditioned media
from these cell lines can sustain growth of non-transformed parental cell lines
(Anderson and Mladenovic, 1996). The presence of an autocrine loop in Bcr/Abl
transformed cells is also found in vivo. Leukemic cells derived from Bcr/Abl
transplanted mice produce excess IL-3 and GM-CSF , this autocrine loop
contributes to CML progression in these animals (Zhang and Ren , 1998).
Although autocrine loops clearly contribute to Bcr/Abl transformation they are not
required for the establishment of GF independence. In fact, the two pathways
leading to GF independence or to the establishment of autocrine loops can be
uncoupled in cells transformed by a Bcr/Abl mutant lacking the SH2 domain
(Bcr/AbI8SH2). Thus, expression of Bcr/AbI8SH2 mutant in a factor-dependent
myeloid cell line induces growth factor independent proliferation but prevents the
production of IL-3 and GM-CSF and conditioned media from Bcr/AbI8SH2 lines
fail to sustain growth of the parental cell line (Anderson and Mladenovic, 1996).
In agreement with these observations, the use of neutralizing antibodies against
IL-3 or GM-CSF in Bcr/Abl transformed cells does not affect GF independence.
Taken together these results suggest that GF independence and establishment
of an autocrine loop are two uncoupled pathways and both of these alterations
contribute to Bcr/Abl cell transformation.
Another strategy to develop autonomous growth is to deregulate cytokine
signaling pathways in order to bypass the requirement of ligand-receptor
interaction. In leukemic cells the most affected cytokine signaling pathway is
JAK/STAT. As described in the previous section , Bcr/Abl constitutively activates
STAT5 and this activation is JAK independent. Interestingly, STAT5 activation in
CML lines is not a consequence of IL-3 or GM-CSF autocrine loop but is directly
correlated to Bcr/Abl tyrosine kinase activity (Chai et aI. , 1997). A possible
mechanism by which ST A T5 mediates malignant proliferation is through the
transcriptional regulation of different genes such as oncostatin M and pim-
Oncostatin M (OSM) is a cytokine that is critical for the development of
multipotential hematopoietic progenitors (Grenier et aI. , 1999). Mice
reconstituted with bone marrow expressing OSM develop myeloproliferative
disease indicating that ST A T5 mediated expression of this cytokine might
contribute to malignant myeloid expansion (Schwaller et aI. , 2000). Pim- 1 is a
serine/threonine kinase that is upregulated in Bcr/Abl expressing cell lines
(Amson et aI. , 1989; Nosaka et aI. , 1999a) and whose expression is STAT5
dependent (Nieborowska-Skorska et aI. , 2002). In addition, exogenous
expression of Pim-1 in hematopoietic cell lines allows GF autonomous
proliferation (Nosaka and Kitamura , 2002). Recently, a Bcr/Abl mutant (Bcr/Abl
L\SH2SH3) that does not activate STAT5 was shown to be defective in Pim-
upregulation. This Bcr/Abl mutant has impaired leukemogenic capacity, which
cannot be restored by overexpression Pim-1 alone but required coexpression of
multiple STAT5 anti-apoptotic targets (Nieborowska-Skorska et aI. , 2002). In
addition , expression of a dominant negative mutant of Pim- 1 does not affect
Bcr/Abl induced growth factor independent proliferation (Nosaka and Kitamura,
2002). Taken together these results suggest that Pim-1 might playa critical role
but it is dispensable for Bcr/Abl induced transformation.
(2) Inhibition of apoptosis
The ability of the Bcr/Abl oncogene to inhibit apoptosis is thought to be
important for survival of CML differentiated granulocytes and for the induction of
clonal expansion in the initial phase of the disease (Bedi et aI. , 1994). Although
the role of Bcr/Abl as an inhibitor of apoptosis has been studied intensively, the
mechanisms by which this inhibition is accomplished are still controversial. The
majority of the proposed mechanisms involve the regulation of Bcl-2 family
members and pathways that lie upstream of procaspase-3 activation (Dubrez et
aI. , 1998). There are three main protagonists in Bcr/Abl anti-apoptotic events
that have been reported: Bad , Bcl-2 and BcIX
Bcl- is the founder of a large family of apoptotic regulators. Both Bcl2
and BcIX carry out their anti-apoptotic function by acting at the level of the
mitochondrial membrane. The expression of the anti-apoptotic factor Bcl-2 is up-
regulated in Bcr/Abl expressing cells (Cirinna et aI. , 2000; Sanchez-Garcia and
Martin-Zanca, 1997). This induction is mediated by the combined action of the
PI3K/Akt (Skorski et aI. , 1997) and the Ras pathways (Sanchez-Garcia and
Martin-Zanca, 1997). Suppression of either Bcl-2 expression or Ras activation
abolishes Bcr/Abl anti-apoptotic properties and blocks tumorigenicity in vivo
(Cortez et aI., 1996; Sanchez-Garcia and Martin-Zanca, 1997). On the other
hand, Bcl-2 overexpression restores the transforming potential of a mutated
Bcr/Abl defective in transformation (Cirinna et aI. , 2000). The mechanism by
which Bcr/Abl induced overexpression of Bcl-2 prevents apoptosis is still poorly
understood. One hypothesis is based on the observation that Bcl-2 might
associate with the serine/threonine kinase Raf- 1 localizing it to the mitochondrial
membrane (Wang et aI., 1994). Here, Raf- 1 is able to negatively regulate the
pro-apoptotic factor Bad by phosphorylation of an important serine residue (see
later) .
Bad is a pro-apoptotic member of the Bcl-2 family which lacks the
mitochondrial insertion signal and therefore is mainly localized in the cytoplasm
(reviewed in (Gross et aI. , 1999a). In normal cells, Bad is found in a
phosphorylated inactive form usually associated with cytoplasmic 14-
proteins. In response to an apoptotic stimulus, Bad becomes unphosphorylated,
it dissociates from 14- 3 and translocates to the mitochondria. Here, active Bad
interacts with membrane bound anti-apoptotic factors Bcl-2 and Bcl . This
association interferes with the anti-apoptotic properties of these two proteins and
triggers cell death. Different studies suggest that Bcr/Abl exerts its anti-apoptotic
activity in part by modulating different steps of Bad- induced death pathway. One
level of regulation is achieved by activating the kinases responsible for Bad
phosphorylation. Constitutively phosphorylated Bad is unable to translocate to
the mitochondria and thus induce apoptosis under stress conditions. Akt and
Raf-1 are likely candidates to accomplish Bad inactivation and indeed both of
these kinases are constitutively activated in Bcr/Abl transformed cells (Neshat et
aI. , 2000; Skorski et aI. , 1997). A second strategy to block Bad- nduced
apoptosis is to inhibit the phosphatase activity of PP- 1 a thus blocking Bad
dephosphorylation (Salomoni et aI. , 2000). An interesting observation is that
Bcr/Abl transformed cells are more resistant to death induced by a mutated form
of Bad in which the regulatory serines are replaced by alanines (Salomoni et aI.
2000). This particular mutant is resistant to phosphorylation-dependent
inactivation. A proposed mechanism envisions Bcr/Abl quenching Bad apoptotic
activity through the overexpression of the anti-apoptotic factors Bcl-2 and Bcl
(Salomoni et aI. , 2000).
As research in the Bcr/Abl field advances additional mechanisms for the
anti-apoptotic activity of this oncogene have been identified. Recently Gelfanov
and coworkers showed a cooperative response between the Ras and the PI-
3K/Akt pathway in Bcr/Abl cells leading to the activation of p65NF-KB and the
transcriptional upregulation of c- IAP2 (Gelfanov et aI. , 2001). This clearly
indicates that other mechanisms are likely to participate in this important aspect
of Bcr/Abl oncogenic activity.
(3) Mitogenic stimulus
The ability to activate mitogenic signaling pathways is one of the important
steps that allow transformed cells to expand rapidly. During the chronic phase
CML cells are still able to differentiate normally but they exhibit increased
prolierative capacity since they undergo extra cycles of cell division as compared
to normal myeloid cells. This cycling ability confers a growth advantage to the
transformed cells allowing the initial expansion of the malignant clone (Clarkson
and Strife , 1993). The subsequent accumulation of secondary mutations
contributes to the increased proliferation rate of CML cells observed in blast
phase. Thus, Bcr/Abl might increase the cellular proliferation in two ways: by
accumulating mutations in important components of the cell cycle machinery; or
direct activation of mitogenic signaling pathways that drive cell cycle progression.
While mutations of cell cycle regulators are frequently found in blast crisis CML
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patients , in chronic phase CML these mutations are uncommon. Thus, in this
phase, the ability of Bcr/Abl to activate mitogenic signaling pathways
particularly important. This mitogenic ability is evident in experiments where
inducible expression of Bcr/Abl stimulated cell cycle re-entry of starved normal
myeloid cells (Cortez et aI., 1997). In these cells the G1-S transition stimulated
by Bcr/Abl is associated with the activation of specific components of the cell
cycle machinery including Cdk2 (Cortez et aI. , 1997) and cyclin D2 (Cortez et aI.
1997; Jena et aI. , 2002). In accordance with these observations , deficiency in
cyclin D2 inhibits Bcr/Abl-nduced cell proliferation in vitro and transformed cells
are arrested predominantly in G1 phase (Jena et aI. , 2002). Interestingly, the
block in Bcr/Abl- induced cell cycle proliferation is observed in bone marrow
derived from either hemizygous cyclin 02+/- or homozygous cyclin 02- This
result might suggest that a threshold amount of cyclin D2 is required in order to
induce G1-S progression in CML cells.
Bcr/Abl induces G1-S transition also through the downregulation of cdk
inhibitors such as p27KiP1 . Regulation of p27KiP1 is achieved through the activation
of the PI3K/Akt pathway (see previous section) and is mediated by proteasome-
dependant degradation (Gesbert et aI. , 2000).
Besides increasing malignant proliferation , Bcr/Abl induced deregulation of
the cell cycle machinery also serves a different function in transformed cells.
Recent reports have shown that Bcr/Abl induces a prolonged G2/M arrest
following irradiation (Nishii et aI., 1996). This delay allows transformed cells to
recover from genotoxic stress and prevents mitotic catastrophe. Thus Bcr/Abl
induced growth arrest observed under these conditions may serve an unusual
anti-apoptotic function.
(4) Altered Cellular Adhesion
In CML, Bcr/Abl+ progenitor cells have selective growth advantage over
normal progenitors cells. This advantage determines the abnormal clonal
expansion that is observed in the initial chronic phase of the disease.
Interestingly, at this initial stage CML progenitors lack responsiveness to signals
from the bone marrow microenvironment. This effect is correlated to the failure
of CML progenitors to adhere to bone marrow stromal layer and to the
extracellular matrix (reviewed by Salesse and Verfaillie, 2002). In normal
progenitors, adherence to the stromal layer is believed to be essential for the
regulation of hematopoiesis since it brings the anchored progenitors to close
proximity of cytokine producing cells. The pluripotent progenitors will determine
their fate depending on the type of extracellular signals they receive from the
neighboring cells. In CML cells , failure to adhere would allow the cells to escape
the differentiation program and to migrate from the marrow into capillaries at an
immature stage of development. Direct contact of the progenitor cells with the
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stromal layer is not required for proliferation, which is stimulated by soluble
factors. However , a substantial increase in myeloid proliferation is observed in
the absence of stromal contact indicating that the stroma mediates an inhibitory
signal (Salesse and Verfaillie , 2002). The adhesion studies that followed these
initial observations are contradictory. The major shortcoming is due to the
variability in adhesion capacity of primary CML cells versus cultured cell lines
and to culture conditions. So while primary CML cells show decreased
adherence , Bcr/Abl expressing myeloid cell lines are tightly anchored to stromal
layers.
In primary CML progenitors (which resemble more closely the adherence
characteristics observed in CML) the decreased adherence is correlated with a
defect in integrin-mediated signaling. Integrins are transmembrane proteins that
form heterodimers consisting of a and 13 subunits. The intracellular domain of the
13 subunit is linked to the cytoskeleton. Upon binding to its ligand the integrins
initiate a signaling cascade that ultimately affects the cytoskeleton structure. In
CML cells, incubation with a 131 integrin-activating antibody restores stromal and
fibronectin adhesion and inhibits cell proliferation (Salesse and Verfaillie, 2002).
These results suggest that reduced binding of the integrin extracellular domain
results in defective intracellular signaling and loss of cell adhesion. Interestingly,
IFN-a induces a significant dose-dependent increase in the adhesion of CML
progenitors to the stroma. This effect is inhibited by the addition of blocking
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antibodies against different integrins (Salesse and Verfaillie , 2002). The
normalization of progenitor-stroma interaction is probably the reason why IFN-a
is successfully used as alternative treatment of CML patients that cannot
undergo allogenic bone marrow transplantation.
The molecular mechanism that links Bcr/Abl to the deregulation of integrin
signaling is still unclear. Among the proteins that tyrosine phosphorylated in
Bcr/Abl expressing cells there are important focal adhesion components such as
CrkL (ten Hoeve et aI. , 1994), Fak (Gotoh et aI. , 1995; Salgia et aI. , 1995a),
p130Cas (Salgia et aI. , 1996), Cbl (Andoniou et aI., 1994) and Paxillin (Salgia et
aI. , 1995b). Inhibition of Bcr/Abl tyrosine kinase activity with PTK inhibitors
(Tyrphostin AG957) reduces the level of tyrosine phosphorylation of these focal
adhesion molecules and increases stromal adhesion (Bhatia et aI. , 1998). These
results suggest that constitutive phosphorylation of focal adhesion components
may impair their ability to mediate integrin signaling leading to decreased
adhesion in CML progenitors.
(5) Limitless replicative potential
One hallmark of oncogenic transformation is the ability of tumor cells to
replicate indefinitely, a process known as immortalization. In contrast , normal
human cells have the capacity for a definitive number of cell duplications (usually
60-70 doublings). The "counting device" that controls the number of completed
doublings is the telomeric ends of chromosomes. Telomeres are composed of
several thousands of repeated 6bp sequence, portions of these stretches are
systematically lost at each replicative event due to the inability of conventional
DNA polymerases to complete synthesis of chromosomal ends (reviewed in
Maser and DePinho, 2002). The progressive erosion of telomeres ends with the
induction of cellular checkpoints that block cell division. This first level of
regulation , known as senescence , prevents the exposure of the unprotected
chromosome ends that could cause karyotipic rearrangements. This first
regulatory mechanism can be breached by the inactivation of cell cycle
regulators such as p53 and Rb. As proliferation continues further telomere
erosion contributes to genomic instability and peaks with massive cell death
known as "crisis . The subset of cells that survive this second proliferation block
usually display massive genetic instability and most probably have acquired the
combination of genetic alterations required for malignant transformation. The
limitless replicative potential is achieved usually by activating telomere
maintenance mechanisms. Among these mechanisms is the activation of a
telomerase reverse transcriptase that de novo synthesizes the 6bp repeats at the
ends of chromosomes. Interestingly, transformed cells exhibit short telomeric
ends compared to the adjacent "normal cells" since they undergo more cell
division that allow the accumulation of the array of oncogenic alteration prior
telomerase activation (Hanahan and Weinberg, 2000; Maser and DePinho,
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2002). In this model , the advent of oncogenic transformation occurs before the
establishment of telomeric maintenance. In accordance to this model is the
finding that telomerase is not required for tumorigenesis and telomerase knock
out mice are more prone to develop tumors. In this new view of the oncogenic
process the telomere dysfunction and subsequent crisis represents a
mechanisms by which a cell accumulates the transforming alterations.
In CML cells, telomere length drastically shortens with progression
between chronic and blast phase. In this latter phase, the acquisition of
cytogenetic aberration is also associated with an increase of telomerase activity
(Brummendorf et aI. , 2000). Different studies have suggested a correlation
between telomere length in blast phase and the onset of blast crisis whereas
shorter chronic phase telomeres are associated with shorter latency to blast
phase and a high frequency of chromosomal rearrangements (Boultwood et aI.
2000; Brummendorf et aI. , 2000). Therefore , telomeric measurement in chronic
phase patients could be an invaluable diagnostic tool for the selection of patients
at high risk of disease transformation.
(6) Genomic instability
The progression of CML to blast phase is usually accompanied by the
appearance of chromosomal defects including duplication of the Ph
chromosome. These macroscopic rearrangements suggest that Bcr/Abl can
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induce genomic instability. The ability to increase the mutation rate is a powerful
mechanism that allows oncogenes to accelerate the process of tumor
progression. One way Bcr/Abl achieves genomic instability is by disabling key
components responsible for the surveillance of genomic integrity. A typical
targeted member of this "surveillance team " is the tumor suppressor protein p53
This protein is a DNA damage sensor that elicits either a cell cycle arrest to allow
DNA repair or apoptosis if damage is excessive. The p53 DNA damage
signaling pathway is lost in most CML cells that reach blast crisis (Chopra et aI.
1999). Besides disabling DNA damage sensors (as in the case of p53), Bcr/Abl
prevents the elimination of cells with excess DNA damage and/or with irreparable
lesions by inhibiting apoptotic pathways (see previous section). The ability to
elude elimination is also useful for transformed cells to survive genotoxic damage
induced by treatment and allows CML cells to tolerate higher levels of DNA
damage compared to normal cells (Skorski , 2002). Interestingly, the level of
DNA damage in CML cells is higher than in normal cells despite the fact that
CML cells can repair most of DNA lesions faster. This facilitated repair is a direct
effect of Bcr/Abl catalytic activity and it may be mediated by the upregulation of
Rad51. Rad51 is functionally similar to the E.coli RecA protein , it is a key player
in the homologous recombination DNA repair responsible for the elimination of
double strand breaks (DSB). Bcr/Abl regulates Rad51 at multiple levels: at the
mRNA level by inducing STAT5-mediated transcription and at a post-translational
level by activating Rad51 ability to associate with DSB through direct
phosphorylation of specific tyrosine residues and by inhibiting caspase 3-
mediated Rad51 degradation (Skorski , 2002). Although Bcr/Abl enhances the
cell' s repair ability, the efficiency of the repair mechanisms may be diminished.
For example, in Bcr/Abl expressing cell lines there is enhanced expression of
DNA polymerase B, which has intrinsic low fidelity. In addition Bcr/AbIP210
thought to hinder the repair capability of the xeroderma pigmentosum group B
protein (XPB) (Takeda et aI., 1999). This effect in combination with the inhibition
of apoptosis and mitogenic stimulation allows the accumulation of mutations that
could result in blastic transformation.
LlI.E. Therapeutic strategies for treatment of Bcr/Abl positive leukemias
Currently allogenic bone marrow transplantation is the only successful
way to eradicate CML. Unfortunately, only 20-25% of CML patients are eligible
for this procedure due to age restraints or lack of a suitable donor. Even in
transplant cases the risk of morbidity and mortality is very high. Other
therapeutic strategies were developed based on the observation that the driving
force of CML is Bcr/Abl tyrosine kinase activity. This activity is not only required
for the initial development of the disease but also for the maintenance of
leukemia. This can be observed in a transgenic mice model where the
expression of Bcr/Abl is regulated by a tetracycline inducible promoter. In these
mice, the increase in Bcr/Abl expression determines the onset of leukemia. After
the disease is established a subsequent inhibition of Bcr/Abl expression induces
remission in all mice indicating that expression of Bcr/Abl is required for the
maintenance of the disease (Huettner et aI. , 2000). Different therapies
developed to lower Bcr/ Abl expression at a translational level by either antisense
oligonucleotide (Gewirtz et aI. , 1998) or ribozyme (James and Gibson, 1998)
strategies; unfortunately these approaches failed to fulfill their initial promise.
However, direct inhibition of Bcr/Abl tyrosine kinase activity turned out to be a
successful strategy. The development of a specific signal transduction inhibitor
(STI571) drastically changed the prognosis of many CML patients (Druker et aI.
1996). Selective inhibition by STI-571 is achieved by binding to the inactive
conformation of the tyrosine kinase. This reversible inhibitor competes for the
Bcr/Abl ATP binding site and blocks the phosphorylation of downstream effectors
(Schindler et aI. , 2000). The drug is specific at micromolar concentrations
although it does affect other tyrosine kinase such as c-Abl and c-Kit. The
therapeutic power of STI-571 is evident in clinical trials where it induced
hematological remission in nearly all chronic phase patients treated with
appropriate doses (Sawyers, 2002). Unfortunately the drug is not as powerful in
blast crisis cases; after an initial hematological response the majority of patients
relapse with a drug resistant form of the disease. Molecular characterization of
CML cells from these patients revealed different drug-resistance mechanisms.
The majority of these mechanisms are Bcr/Abl dependent and include gene
ampliication of the oncogene and specific mutations of Bcr/Abl kinase domain
that hinder STI-571 binding (Nimmanapalli et aI. , 2002; Sawyers , 2002). These
observations suggest that blast phase.
CML cells are genetically unstable and normally accumulate mutations
during disease progression. In this context, STI-571 selects for the drug resistant
alleles that cause the observed relapse. In order to circumvent the occurrence of
resistance novel therapies combine STI-571 with traditional chemotherapy.
Although there are some encouraging results (Nimmanapalli et aI. , 2002;
Thiesing et aI. , 2000) the search for the optimal drug combination is still in
progress. The elucidation of critical steps in the intracellular signaling pathways
will be pivotal in the identification of additional molecular targets for effective
therapeutic compound.
CHAPTER II
MATERIALS AND METHODS
(1) Plasmids
A bicistronic MSV retroviral vector, and vectors expressing v-Abl
Bcr/Ab1P185 or Bcr/AbIP210 or JBD have been described (Dickens et aI. , 1997;
Muller et aI., 1991). An MSCV- IRES-GFP retroviral vector (Zindy et aI. , 1998)
was used for in vivo bone marrow reconstitution assays. Bcr/Abl isoforms (EcoRI
fragment from the corresponding MSV vectors) were cloned in the corresponding
Eco RI restriction site of the MSCV- IRES-GFP vector. The plasmid
expressing retroviral packaging proteins was provided by Charles Sawyers.
The Dbl domain of Bcr/AbIP210 (aa 413-789) was amplified by polymerase
chain reaction (PCR) using the following primers 5' GCGAGTGAATTCGACTTGG-
AAAAGGGCTTGGAG-3' and 5' GCTGTGCTCGAGCTGGAGTTTCACACACGAGTTG-
. The amplicon was digested with EcoRI and Xhol and ligated into the
corresponding restriction sites of pCMV-Tag2B (Stratagene) in frame with the
Flag epitope tag. Bcl2 promoter reporter plasmid (LB334; (Wilson et aI. , 1996)
was provided by Linda Boxer and was used in cotransfection assays with the
Renila reniformis luciferase plasmid pRLnull (promega).
(2) Mice
C57BL6 mice expressing Bcl-2 under the I- enhancer IgH promoter
(Strasser et aI. , 1991) and wild-type C57BL6 mice were obtained from The
Jackson Laboratories. Jnk1 /- mice were described previously (Dong et aI.
1998). The animals were housed in a facility accredited by the American
Association for Laboratory Animal Care.
(3) Cell lines: Culture , Transfection protocols and Viral Production.
293T and NIH3T3 cells were cultured in Dulbecco modified Eagle medium
(DMEM) supplemented with 10% Fetal Bovine Serum (FBS)(Omega scientific,
Hyclone) 2mM L-Glutamine (Life Technologies), 100 U/ml penicilin and 1001-g/ml
Streptomycin (Life Technologies). For the analysis of the Dbl domain described
in section III.II.C subconfluent 293T cells were transfected with 11-g of either
Flag-Dbl plasmid or pcDNA3 as a empty vector control using Superfect (Gibco)
following the manufacturer s protocol. The endogenous JNK activity of the
transfected cells was analyzed 48 hours post transfection. 293T cells were also
used to produce viral supernatants. For this purpose subconfluent plates (80%)
were cotransfected using Superfect with equal amounts of the retroviral plasmid
of choice and the Weco plasmid. Cells were incubated in growth media for 24
hours post transfection and then shifted to Virus Collecting medium (VCM)
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(Iscove s Modified medium with 10% FBS, 2mM L-Glutamine (Life Technologies),
100 U/ml penicillin and 1 OOllg/ml Streptomycin (Life Technologies)). Culture
supernatants containing virus were collected starting 40 hours up to 72 hours
post transfection. After each collection the cultures were replenished with fresh
VCM medium. All collected aliquots of viral supernatant were pooled , cleared by
centrifugation and filtered through a 0.451l filter. The filtered aliquots were stored
at - C. Viral titers for the MSV retroviruses were measured by infecting
murine cells (NIH3T3) with serial dilutions of viral supernatants. The infections
were carried our by incubating exponentially growing cells overnight at 37 C 5%
with retroviral supernatants in the presence of 8llg/ml hexadimethrine
bromide (Polybrene) (Sigma). 48 hours post infections cells were transferred to
150mm dishes and cultured in selection media (growth media containing
2001lg/ml of Geneticin (G418 , Gibco). Media was routinely replaced every 48
hours. Two weeks post infection plates were analyzed for the presence of G418-
resistant colonies in the different viral dilutions. Viral titers for the MSCV
retroviruses were estimated by infecting equal numbers of Baf3 cells with serial
dilutions of viral supernatant. Infected cells were analyzed by flow cytometry 48
hours post infection for the presence of GFP+ cells. The percentage of GFP+
cells in a specific dilution would give an estimate of the viral titer. All infected
cells were analyzed by immunoblot for Bcr/Abl expression.
Baf3 were cultured in growth media (RPMI medium supplemented with
5ng/ml recombinant mouse Interleukine-3 (IL-3) (R&D System), 10% Fetal
Bovine Serum (FBS)(Omega scientific , Hyclone) 2mM L-Glutamine (Life
Technologies), 100 U/ml penicillin and 1 OO g/ml Streptomycin (Life
Technologies)). Baf3 stable cell lines expressing Bcr/AbIP185 , Bcr/AbIP210 or empty
vector control were generated by retroviral infection using MSV retroviral
constructs. Equal number (10 cells) of exponentially growing cells were
incubated overnight at 37 C 5% CO with retroviral supernatants in the presence
of 0.5ng/mIIL-3 and 8 g/ml Polybrene (Sigma). After 16 hours cells were
washed and resuspended in fresh growing media at a concentration of 2x10
cells/ml. 48 hours post infection cells were transferred to selection media
(growth media containing 400 g/ml Geneticin (Gibco)), uninfected cells were also
plated as negative controls. After two week of selection samples from each
culture were analyzed by western blot for Bcr/Abl expression. Stable cell lines
were routinely cultured in selection media. For the SP600125 experiments
described in Results (section III.I.B) 2x10 cells (Baf3/p185 or Baf3Nector
control) were cultured in 10ml of growth media with or without 0.5ng/ml IL-3 in
the presence of either 20 M SP600125 (Biomol) or dimethyl sulfoxide (DMSO)
(Sigma). The DMSO concentrations in all samples was 0.2%. Cells were treated
for either 16 hours (for BrdU and trypan blue viability assays) or 24 hours (for
Annexin V labeling) and cell viability was evaluated by counting trypan blue
negative cells in each culture. Equal number of cells were analyzed by flow
cytometry. For the transient transfection experiments described in section IILlI.B
equal numbers of exponentially growing Baf3 cells (Baf3/p210 and Baf3Nector)
(5x10 cells/sample) were washed twice in serum-free media (RPMI with no
supplements) and resuspended at a concentration of 10 cells/ml. Cells were
aliquoted (0.5 ml) in electroporation chambers and incubated for 1 Om in at room
temperature with a DNA mixture containing 4 g of Bcl2 promoter reporter
plasmid , 0. g of pRLnull and 8 g JBD (when indicated) plus varying amounts of
pBluescript II KS+ (Stratagene) as a carrier in order to reach total DNA content of
30 g. Cells were electroporated (250V, 1180 , low Q) using an Invitrogen
Cellporator and immediately placed on ice for 10 min. Following this incubation
cells were allowed to recover in growth media for 48 hours before analyzing
luciferase activity.
S17 cells (Collins and Dorshkind, 1987) were routinely cultured in aMEM
supplemented with 20% FBS (Omega scientific , Hyclone) 2mM L-Glutamine (Life
Technologies), 100 UI/ml penicillin and 100 g/ml Streptomycin (Life
Technologies). For the production of stromal layers, S17 cells were allowed to
reach confluency and then they were placed in Lymphoid media (RPMI5% FBS
5x1 0. M 2-mercaptoethanol (f3ME) 2mM L-Glutamine (Life Technologies), 100
U/ml penicilin and 1 OO g/ml Streptomycin (Life Technologies)) for two days to
prepare conditioned media to sustain the growth of primary lymphoblast (see
primary cultures section).
(4) Primary cells: cultures , Bone marrow assay
For bone marrow assays described in section III. , I followed the
protocol for high density bone marrow long term culture described in (Whitlock et
aI. , 1984). Bone marrow cells were isolated by flushing tibias and femurs of 4
week-old male mice. Cells were resuspended in Lymphoid media and cell
density was determined by counting cells in 0.2% methylene blue and 3% acetic
acid which preferentially lyses erythrocytes. Equal numbers of cells
(1.5x10 cells) were infected with the desired virus in the presence of 8 g/ml
Polybrene for 3 hours at 37 C 5%C0 . After infection cells were washed with
Lymphoid media and plated in three 60mm dishes (5x10 cells/dish). Culture
plates were set on a tray wrapped with aluminum foil and placed in 37 C 5%C0
incubator. Cells were routinely fed every three-four days by either adding a 2 ml
of fresh lymphoid media (on day 3-4 post infection) or by removing 75% of
medium without removing non-adherent cells and adding 4 ml of fresh media (on
day 7 post infection). The routine feeding schedule was repeated every week for
the entire duration of the assay. Starting 12 days post infection aliquots were
taken from each culture every two days and cell density was measured by
counting trypan-negative cells with a hemocytometer.
(5) Leukemogenic transformation assays and "ex vivo" cultures
We used two different methods of in vivo reconstitution that would give
rise to either Bcr/Abl induced lymphoid or myeloid disease in recipient mice. For
the " lymphoid" reconstitution protocol , bone marrow cells were isolated from
tibias and femurs of donor male mice (4 week-old) and transduced with MSCV
retroviruses (Bcr/AbI P185 , Bcr/AbIP210 and empty vector control) following the same
infection protocol as for the bone marrow assay described above. Three hours
post infection , the transduced bone marrow was washed once in lymphoid media
and resuspended in sterile Phosphate buffered saline (PBS) at a concentration of
2x10 cells/ml. Transduced bone marrow cells (10 ) were injected into the tail
vein of lethally irradiated (2x525 Rads each dose administered 4 hours apart)
C57BL6 recipient mice (8 week-old females). Secondary transplantation assays
were performed using non- lethally irradiated (1 x 450 Rads) mice (8 week old
C57BL6 females). All recipient mice were monitored daily for signs of morbidity
and weight loss. Premoribund mice were euthanized by cervical dislocation.
For the "myeloid" reconstitution protocol donor mice (4 week-old males)
were treated with a single dose of 10mg/ml 5-Fluorouracil (5-FU) (0.008ml/gr of
body weight) 3 days prior harvest of the bone marrow. The bone marrow was
transduced with MSCV retroviruses (Bcr/AbIP185 , Bcr/AbIP210 and empty vector
control) and C57BL6 mice were reconstituted using the same protocol as
described for the "lymphoid" reconstitution assay. All recipient mice were
monitored daily for signs of morbidity and were euthanized 15 days post
reconstitution.
White blood counts were performed on all recipient mice twice a week
using the Unopette microcollection system (Becton Dickinson). After
euthanization the organs from the recipient mice were harvested , weighed, fixed
in 4% paraformaldehyde, processed for paraffin-embedded sectioning, and
stained with hematoxylin and eosin. Femurs were treated with Decalcifier-
(Surgipath Medical Ind. ) overnight prior to fixation. Whole bone marrow was
harvested from tibias and femurs and treated with red blood cell lysis solution
ACK (0. 15M NH , 1mM KHC0 and 0. 1mM disodium EDTA (ph7.3)) (Zhang
and Ren , 1998). Cells were counted and aliquots were cytocentrifuged onto
slides and stained with Diff Quik (Dade Behring AG) following manufacturer
recommendations. Bone marrow was also analyzed by flow cytometry for the
expression of surface markers (see later).
Cells isolated from the bone marrow of the recipient premoribund mice
were cultured in vitro following the bone marrow long term culture protocol
described for the bone marrow assay (Whitlock et aI. , 1984). After one week
non-adherent cells were harvested and plated onto confluent S17 stromal layers.
The cells obtained were routinely passaged on stromal layers. To examine the
dependence of the cells on the stromal layer, the cells were washed with media
and plated in the presence and absence of the stromal layer (1 06 cells/1Oml).
BrdU labeling and Annexin V assays were performed 3 days post plating.
(6) Immunoblot Analysis
Cells were lysed in Triton Lysis Buffer (TLB) containing 20mM Tris
(pH7.4), 137mM NaCI , 2mM sodium pyrophosphate, 1% Triton X- 100, 10%
glycerol , 2mM EDTA, 25mM f)-glycerophosphate, 1 mM sodium orthovanadate
1 mM phenylmethylsulfonyl fluoride , 0.5mM dithiothreitol and 5""g/ml of aprotinin
and leupeptin. Lysates were incubated for 10 min on ice and then they were
cleared by centrifugation (13,000rpm for 15 min at 4 C). The protein content 
the Iysates was quantified by Bradford Assay (Biorad) and equal amount of total
protein was resolved on SDS-PAGE. Proteins were transferred
electrophoretically onto polyvinylidene difluoride membrane (Immobilon). The
membrane was blocked following the antibody manufacturer s protocols.
Immunoblots were probed with antibodies to Abl (Gaga et aI. , 1995), JNK
(Pharmingen), Flag epitope (Kodak and Sigma), Akt (Cell Signaling), phospho-
Ser473 Akt (Cell Signaling), Bcl-2 (Pharmingen) and phosphotyrosine (Py-99;
Santa Cruz). Immune complexes were detected by enhanced
chemiluminescence (NEN).
(7) Protein Kinase Assays
Two different procedures were used to measure JNK kinase activity: GST-
pull down and immunocomplex kinase assay. The GST pull-down assay was
performed to analyze JNK activity in primary cells. These cells were lysed in TLB
and then quantitated by Bradford. Lysates (50j.g) were incubated with GST-cJun
(aa 1-223) bound to Glutathione-Sepharose 4B beads (Amersham Pharmacia)
for 2 hours at 4 C. Beads were washed twice with TLB and twice with Kinase
Buffer (25mM Hepes (pH 7.4), 25mM f3-glycerophosphate , 25mM MgCI2 , 0. 1 mM
sodium orthovanadate, 0.5mM dithiothreitol). The kinase reaction was carried
out at 30 C for 15 min in a final volume of 25j.1 kinase buffer containing 50j.M
ATP (370 kBq/nmol) and 20j.M ATP. Laemmli buffer was added to stop the
kinase reaction. Immunocomplex kinase assay were used to evaluate JNK
kinase activity in transfection assays (Fig. 12). In this assay, equal amounts of
TLB Iysates were immunoprecipitated by incubation for 3 hrs at 4 C with 1 j.g of
JNK antibody pre-bound to Protein-G Sepharose beads (Amersham
Pharmacia). Immunocomplexes were washed twice with TLB and twice with
Kinase Buffer. The kinase reaction was carried out at 30 C for 15 min in a final
volume of 25j.1 kinase buffer containing 50j.M A TP (370 kBq/nmol) and
20j.M ATP and 2j.g of GST-Jun (aa1-223). All kinase reactions were resolved
on SDS-PAGE 12% gel and the phosphorylation of GST-cJun was quantitated
using a Phosphoimager (Molecular Dynamics).
(8) Luciferase reporter gene assays
Bcl2 promoter activity described in section II.B was analyzed using a dual-
luciferase reporter assay (Promega) following manufacturer s protocol.
Transfected cells were lysed in passive lysis buffer (PLB; provided by the
manufacturer). Ceillysates were subjected to three freeze/thaw cycles and then
spun for 10min 15,000xg 4 C. Aliquots of the ceillysates were added to
luciferase substrate (LARII) luminescence were immediately quantitated using a
luminometer (Monolight 2010; Analytical Luminescence Lab.). The firefly driven
reaction was quenched and the substrate for the Renilla luciferase was added by
supplementing the reaction with Stop&Glo reagent (promega). Renila induced
luminescence was quantitated and these values were used to normalize the
transfection efficiency between samples.
(9) Immunofluorescence analysis
Whole bone marrow was harvested from tibias and femurs and spleen
were dissected from the euthanized mice. Dissociated cells from the spleen and
bone marrow cells were treated with red blood cell lysis solution ACK. For
immunophenotyping by flow cytometry, equal numbers (10 /sample) of trypan
negative cells were blocked with anti-mouse CD16/CD32 (Fcyili/l receptor;
Pharmingen). Cells were stained with allophycocyanine (APC) conjugated anti-
CD45R/B220 and phycoerythrin (PE)-conjugated anti- Thy1. , CD43 , CD11 b
(Mac- 1a chain), Ly-6G (Gr-1), CD19, Ly-6AE (Sca-1), IgG, IgM , Ly-51 (6C3/BP-
1) or Ter119 (Pharmingen). Cell cycle analysis was performed using cells pulse-
labeled (15 min for primary cells and 1 hour for Baf3 cell lines) with 10!-M BrdU
fixed in 70% ethanol , and stained with DAPI (Molecular Probes) and an antibody
to BrdU (FITC- or PE-conjugated) (Pharmingen) following manufacturer
protocol. Cell death was examined by co-staining with either a combination of
Annexin V FITC-conjugated and Propidium iodide (PI) (Pharmingen) or AnnexinV
PE-conjugated (Pharmingen) and 7-aminoactinomycin D (7-AAD; Sigma).
Staining was performed following manufacturers ' recommendations. Flow
cytometry was performed using a MaFia FACS machine (Cytomation) and a
FACScan (Becton Dickinson). The extent of apoptosis was calculated as a ratio
between AnnexinV+ (apoptotic) cells and Annexin V- (live) cells in the 7AAD-
population (apoptotic index). In the experiments described in Fig. 11 the
apoptotic index was normalized to the basal death observed in untreated
samples in the absence of IL-3. TUNEL assays (Roche) were performed
according to the manufacturer s protocol and were examined by conventional
Immunofluorescence microscopy.
(10) Ribonuclease protection assays
Total RNA was extracted from ex-vivo cultures exponentially growing on
S17 stromal layers utilizing the RNeasy Mini kit (Qiagen) and following the
manufacturer s protocol. Cells were lysed in a guanidinium isothyocyanate
buffer. Lysates are passed through a silica based column that traps total RNA.
Following serial washes with ethanol based solutions the total RNA was eluted
with 301-1 of diethylpyrocarbonate-treated (DE PC) water. The RNA was
quantified and the purity determined by measuring the absorbance at 260 and
280nm using an Ultraspec (Pharmacia). Samples were aliquoted and stored at
C until use. Multi-probe ribonuclease protection assays were performed with
the Riboquant RPA kit by Becton Dickinson-Pharmingen and following the
manufacturer s protocol. Multi-probe templates were radiolabeled with 101-1 of a-
Uridine triphosphate (10I-Ci/l-l; NEN) by T7 RNA polymerase for 1 hour at
C. The reaction was treated with DNAse and extracted with phenol:
chloroform (1:1 vol/vol). The resulting aqueous phase was chloroform extracted
and total RNA was precipitated by adding ammonium acetate (final concentration
of 0.57M) and 100% cold Ethanol. Precipitation were incubated for 30 min at -
C. Samples were spun 15,000xg for 15 min at 4 C and pellets were washed
once with ice cold 90% Ethanol. Dried pellets were resuspended in 8ml of
hybridization buffer (supplied by the manufacturer). Heat denaturated samples
were hybridized overnight to the labeled probe (21-1 of 4x1 OScpm/l-l) by slow
temperature shift (from 90 C to 56 C). The hybridized RNA was digested with
RNAse (250U/ml), phenol: chlorophorm extracted and precipitated as before.
Dried pellets were resuspended in 5ml of loading buffer (supplied by the
;; .
manufacturer). 1.5x1 OS cpms of the unhybridized template set(s) and the total
volumes of the hybridized samples were resolved on a 6% denaturating
polyacrylamide gel. Gels were exposed to a Phosphoimager (Molecular
Dynamics) for quantification and to fim for autoradiography.
(11) Statistical Analysis
Calculation of mean and standard deviation (SD) and standard error of the
mean (SEM) was performed using Microsoft Excel 98. The statistical analysis of
organ weights and survival curve data was performed using Survival Tools for
StatView5 (Abacus Concepts, CA) using the Mantel-Cox (log-rank) test and
Kaplan- Meier survival analysis. The statistical analysis of the in vivo data was
carried out by Joanne Wu and Qui Liu.
CHAPTER III
RESUL TS
111.1. In vitro Approach
Initially I investigated the role of JNK in cell transformation using an in vitro
approach. For this purpose I used Bcr/Abl as a transforming agent since
previous studies indirectly linked the JNK pathway to Bcr/Abl- induced cell
transformation. I examined the effect of JNK gene disruption in Bcr/Abl
transformation using in vitro bone marrow assays (McLaughlin et aI. , 1987) to
study the effect of Bcr/Abl on lymphoid malignant proliferation. Preliminary
experiments described in section II I. LA show that JNK1 is the predominant
isoform in Bcr/Abl transformed lymphoblast. This finding allowed me to use
Jnk1-
/- 
mice for my in vitro assays and thus circumvent the unavailability of
Jnk1-/- Jnk2-
/- 
mice which die at an early embryonic stage. Interestingly, the
results obtained from the in vitro bone marrow assays suggest that while JNK1
plays a critical role in Bcr/AbIP210 lymphoid expansion it is dispensable for
Bcr/Ab1P185 induced transformation (section III.I.B). One possible explanation for
this result is that JNK2 compensates for the absence of JNK1 in Bcr/Ab1P185
transformed lymphoblast. To test this hypothesis I used a pharmacological
approach to deplete JNK activity in pro-B cells transformed by Bcr/AbIP185 . The
results of these experiments are described in section III.I.C.
In addition , the results of the bone marrow assays provide evidence of a
functional difference between Bcr/Ab1P185 and Bcr/AbIP210. These two isoforms
have defined structural differences which include a GEF domain with high
homology to the Dbl proto-oncogene present in the Bcr/AbIP210 and not in the
Bcr/Ab1 P185 isoform. Thus, I investigated whether this domain had a role in the
activation of the JNK pathway by testing the induction of JNK activity by transient
expression of the isolated Dbl domain (section III.I.D).
III. LA. JNK1 is the predominant isoform in transformed pre-B cells
To investigate the role of JNK in leukemogenesis, I examined the effect of
Jnk1- JNK gene disruption in experiments
using the oncogene Bcr/AbIP210. Lethally
.. 
cJun
irradiated mice were reconstituted with
.p54 JNK
.p46 JNK wild-type (WT) and Jnk1-
/- 
bone marrow
.. Tubulin cells transduced with a retrovirus that
Fig. 6 Measurement of IN K activity in cell lines
derived from reconstituted mice. These cells
were cultured in vitro and exposed in the pres-
ence or absence of 60Jlm2 of UV light and JNK
kinase activity was measured by in vitro kinase
assay (KA) using c-Jun as a substrate. Cell
extracts were examined by immunoblot (IB) anal-
ysis using anlibodiestoJNK and Tubulin. JNK1
and JNK2 are expressed as groups of isofororms
of approximately 46-kD and 54-kD. The major
JNK1 and JNK2 isoforms are 46-kD.
expresses Bcr/AbIP210. The cells from the
reconstituted bone marrow were isolated
and levels of JNK activity were
measured. High levels of JNK protein
kinase activity was observed in extracts prepared from wild-type cells after
exposure to UV light (Fig. 6). In contrast, a severe reduction in JNK activity was
detected in Jnk1-
/- 
cells. This observation correlates with the results of
immunoblot analysis that indicated high levels of JNK1 and low levels of JNK2 in
wild-type cells (Fig. 6). The residual JNK2 levels found in Jnk1-
/- 
cells did not
seem to contribute substantially to the JNK kinase activity after UV exposure
(Fig. 6). These data demonstrate that JNK1 is the major JNK in these cells.
Since Jnk1- Jnk2-
/- 
mice are not viable (Kuan et aI. , 1999; Sabapathy et aI.
1999), I focused our analysis of Bcr/AbIP210 on Jnk1-
/- 
mice.
III. LB. In vitro transformation by Bcr/AbIP210 is impaired in Jnk1-
/- 
bone
marrow cells
To examine the potential role of JNK in transformation , I investigated the
effect of the Bcr/Abl oncogene using bone marrow assays in vitro to measure the
outgrowth of transformed pre-B cells (McLaughlin et aI. , 1987). Comparison of
bone marrow from wild-type and Jnk1-
/- 
mice demonstrated no differences in the
relative abundance of cell lineages monitored by flow cytometry (Fig. 7A). The
bone marrow was transduced with retroviruses that express Bcr/AbIP210
Bcr/AbI P185. Control experiments were performed using a retrovirus without
Bcr/Abl (Vector). Both Bcr/Abl isoforms caused outgrowth of transformed pre-
cells in cultures of wild-type (WT) bone marrow (Fig. 7B). Bcr/Ab1P185 caused
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Fig. 7 JNK1 is required for Bcr/Ablp210 induced cell transformation in v/1ro.
(A) Analysis of whole bone marrow derived from WT(blue) and Jnkf.l. (red) mice by flow cytometry. Cells
were analized for the indicated surface markers. (B) In vitro bone marrow assay performed using mouse bone
marrow derived from WT and Jnkt-J- mice transduced with retroviruses (Vector, Bcr/Ablp185 , Bcr/Ablp21 0).
Non.adherent cells were harvested and the mean number of tryptan blue negative cells was measured. Simi.
lar data were obtained in three independent experiments. (C) and (E) Immunoblot analysis of WT and Jnk1-
transformed cells using antibodies to Abl(C) and JNK(E). (D) Non-adherent pre-B cells (14 days post-
infection) were put labeled (15 min) with BrdU and stained with DAPI and a FITC-conjugated antibody to
BrdU. The percentage of cells (mean:tSD. n=3) In G1, Sand G2 phases of the cell cycle was measured by
flow cytometry.
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rapid outgrowth of pre- B cells in Jnk1-
/- 
cultures. In contrast, the outgrowth of
pre- B cells in Jnk1-
/- 
cultures transduced with Bcr/AbIP210 was severely reduced
(Fig. 7B). This reduced outgrowth caused by Bcr/AbIP210 in Jnk1-
/- 
was not due to
differences in Bcr/Abl expression (Fig. 7C), nor to a cell cycle defect (Fig. 70).
Furthermore , transformation by Bcr/Abl did not increase JNK2 expression in
Jnk1-
/- 
cells (Fig. 7E). The absence of a detected cell cycle defect suggested
that the failure of the Jnk1-
/- 
Bcr/AbIP210 cells to accumulate might be caused by
increased cell death (Section IILlII.A). Together these data indicate that JNK1
plays a critical role in Bcr/AbIP210 transformed cells. The proliferation defect in
Jnk1- Bcr/AbI P210 cells may be caused by an inability of the Jnk1-
/- 
stroma to
support the growth of the transformed cells. To test this hypothesis, Bcr/AbIP210
transformed cells were harvested from the in vitro bone marrow cultures
-- - 
Jnk1-
. WT
Jnk1-100
p185
'g 75
100
p210
'i 075
c::
Days post plating Abl
Fig. 8 The lack of proliferation in Jnk1.
;" 
Bcr/Ab1p21O is not due to a defect in stromal support (A) or in intrinsic
transduction efficiency (B).
(A) Equal numbers of BcrJAbl transformed cells were plated onto stromal layers formed by S17 cell line..
Proliferation at different times was measured by counting trypan blue negative cells. Similar data were obtained
in three independent experiments.
(B) Primary mouse bone marrow cells derived from WT and Jnk1-f. mice were infected with a retroviral vector
that expresses v-Abl. Non.adherent cells were collected and the mean number of trypan-blue negative cells
was measured on day 15 after infection.
and equal numbers were plated on wild-type and Jnk1-
/- 
stromal layers or on
stromal layers formed by the S17 cell line. Rapid proliferation of wild-type cells
and Bcr/Ab1P185 transformed Jnk1- lymphoblasts was observed on each of these
stromal layers. In contrast , the Bcr/AblP210 transformed Jnk1-
j- 
cells failed to
proliferate (Fig. 8A). These data indicated that the effect of JNK-deficiency on
the proliferation of Bcr/AbIP210 transformed cells was an autonomous defect in the
transformed cells and was not related to the genotype of the stromal cells.
One possible explanation of the observed transformation defect is that the
number of targeted cells transduced by the Bcr/Abl retrovirus was reduced in the
Jnk1-
/- 
bone marrow. However, the absence of cell lineage and cell number
defects (Fig. 7A) in Jnk1-
/- 
bone marrow is inconsistent with this hypothesis.
Indeed, the observation that Bcr/Ab1P185 (Fig. 7B) and v-Abl (Fig. 8B) caused
similar transformation of bone marrow isolated from wild-type and Jnk1-
/- 
mice
demonstrated that differences in transduced target cell number does not account
for the Jnk1-
/- 
specific defect in transformation caused by Bcr/AbIP210
III.I.C. Both JNK1 and JNK2 activities are required for Bcr/Ab1P185 induced
growth factor- independent growth of Baf3 cells.
The results in the previous section showed that Bcr/Ab1P185 was able to
induce transformation in the absence of JNK1 in bone marrow assays. This
observation led to the hypothesis that in the absence of JNK1 this oncogene
might rely on the presence of JNK2 to induce transformation in vitro. To verify
this hypothesis I tested the ability of Bcr/Ab1P185 to induce transformation in the
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Fig. 9 Inhibition of JNK activity by SP600125 blocks IL 3 independent proliferation in Bcr/Ablp185
transformed Baf3 cells. (A) The JNK inhibitor SP600125 was tested in Baf3 cells exposed to 60 J/m UV light
Celilysates were harvested after 45 min of incubation. JNK activity was measured by in vitro kinase assay
and Iysates were analyzed by immunoblot using JNK antibodies. (B) Equal numbers (2x105) of Bat3 cells sta-
bly expressing Bcr/Ablp185(p185) or vector control (Vector) were plated in the presence or absence at IL-3
and treated with either 20!kM SP600 125 or DMSO. Trypan blue negative cells were counted 16 hours alter
plating (mean:lSD, n::3).
absence of both JNK1 and JNK2 kinase activities. In order to circumvent the
unavailability of Jnk1- Jnk2-
/- 
double knock out mice , which die in utero I took
advantage of the JNK inhibitory drug SP600125. This drug was shown to
specifically inhibit all JNK isoforms in the micromolar range (Fig. 9A Bennett et
aI. , 2001). As a model system I used the pro-B cell line, Baf3. This cell line is
normally IL-3 dependent but upon Bcr/Abl expression it becomes IL-
independent. This acquired growth factor independence is a hallmark of Bcr/Abl
induced transformation. Baf3 lines stably expressing either empty vector
(Vector) or Bcr/Ab1P185 (p185) were made by retroviral transduction and cells were
No IL-
No IL-3
+Drug
'00
'00
,..
'00
, .
w: 
:: a :l M) MI 1300 100
1: .-
0- 20 40 Ei aDO t 00
'''
100 '00
100
... ,..
p185
,..
20 oo 60 &00 I DI
'00
20 400 60 800 1 00
IL-
100
'E 50
100
-E 
+ IL-
+ IL-3
+Drug
'00
,.
'00'
I) 20 400 i& flOG I tO
Vector'00 100
20 4&0 i3 BOO 100
HkK '00
20 40 GO Soo t-O 20 dO 60 aM ICi
+ IL.3 DG1
rJ G2
100
Vectorr/ 50
I. 25
SP600125
100
p185
SP600125
Fig. 10 Baf3 cell lines expressing Bcr/Ablp185 (p185) or vector control (Vector) were treated with 20l!M
SP600125 (Drug) in the presence or absence of IL-3 for 16 hours. Cells were then pulse labeled (one hour) with
BrdU and stained with propidium iodide (PI) and FITC-conjugated antibody to BrdU. The distribution of cells in
different phases of the cell cycle was analyzed by flow cytometry (top panel) and percentage of cells (mean:t
, n=3) in G1, Sand G2 phases was measured (bottom panel).
routinely cultured in the presence of IL-3. Upon removal of IL-3 cell proliferation
was inhibited in the Baf3Nector line while Baf3/p185 growth was unaffected and
these cells underwent a single doubling during the 16 hours experimental time
course (Fig. 9 and 10). The combination of IL-3 removal and treatment with
20l-M SP600125 drastically inhibited cell proliferation in Baf3/p185 and further
exacerbate the reduction in cell number in Baf3/Vector cell line (Fig. 9B). This
reduction in cell proliferation induced by SP600125 in the absence of IL-3 was
due predominantly to a substantial increase in apoptosis as shown by the relative
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Fig. 11 Cell death was analyzed by Annexin V assay of Baf3 stable ceillinss (Vector and p185). Cells were
stained with Annexin V-FITC and propidium iodide (PI) after 24 hour treatment with 20J.M SP600125 (Drug)
in the presence or absence of IL-3 and analyzed by flow cytometry (upper panels). The normalized ratio
between the number of annexin-positive (apoptotic) cells and annexin-negative (live) cells in the PI negative
population (apoptotic index) is presented (mean:!SD, n=3;lower panel).
amount of Annexin V+ cells in the drug treated samples compared to the
untreated controls (Fig. 11). This increase in cell death induced by treatment
with SP600125 in the absence of IL-3 also correlated with the expansion of the
subG1 population observed in our cell cycle experiments (Fig 10 upper panels).
These experiments provided evidence that the drug treatment in the absence of
IL-3 did not affect the overall cell cycle distribution in either Baf3/Vector or
Baf3/p185 cell lines (Fig. 10). The observed SP600125- induced apoptosis was
rescued by the addition of IL-3 in both cell lines (Fig. 11). Taken together these
data suggest that JNK is required for Bcr/Ab1 P185 induced growth-factor
independent cell proliferation.
Although IL-3 completely rescued SP600125- induced apoptosis, it was
interesting that both cell lines , Vector and p185 , still showed reduced proliferation
after drug treatment compared to DMSO-treated counterparts (Fig. 9B). Careful
analysis of Baf3Nector and Baf3/p185 cells revealed that SP600125 induced a
G2 cell cycle arrest in the presence of IL-3 (Fig. 10). This observation suggested
that SP600125 has dual effect in Baf3 cell lines: in the presence of IL-3 it arrests
the cell cycle in G2 while in the absence of IL-3 it causes cell death. The
possible causal relation between these two events needs further investigation.
III.I.D. The Dbl domain of Bcr/AbIP210 is sufficient to activate JNK
The transformation defect described in section III.I.A is the first reported
functional difference between the two isoforms Bcr/AbIP210 and Bcr/AbIP185. This
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Flg. 12 Expression of IBcrAblp210 Obi
domain in 293T cells induces JNK activa-
tion.
JNK activity of cells expressing the Obi
domain of Bcr/Ablp210 (Flag-Obi) was
measured by in vitro kinase assay (KA)
(mean:tSD, n:3). Cells exposed in the
absence or presence of 60 J/m UV light
were used as positive controls. Cell
Iysates were examined by immunoblot
analysis using antibodies to the Flag
epitope and JNK.
prompted the analysis of the two isoforms in
search of structural differences that would
correlate with the observed phenotype. As
previously mentioned in the Introduction
(section LlI.B), Bcr/Ab1P185 and Bcr/AbIP210 differ
exclusively in the Bcr portion of the fusion
oncogene. In particular, only Bcr/AbIP210
contains a region of the Bcr gene that includes
a GEF domain with high homology to the Dbl
proto-oncogene (Dbl domain). This "Dbl
domain" includes two adjacent regions: a Dbl
homology domain (DH) followed by a Pleckstrin
homology domain (PH). The isolated Dbl
domain of Bcr/Ab1P210 has been shown to
activate CDC42, a member of the Rho family of small GTPases (Korus et aI.
2002). Since CDC42 can activate JNK (Coso et aI. , 1995; Minden et aI. , 1995) I
sought to verify whether the Dbl domain derived from Bcr/AbIP210 could trigger the
JNK signaling pathway. Overexpression of the Dbl domain in 293T cells induced
a 6.7 fold increase in JNK activity compared to vector alone (Fig. 12). This result
suggests that Bcr/AbIP210 and not Bcr/Ab1P185 could activate JNK through its Dbl
domain.
111.1. E. Concl usions
In this section I analyzed the requirement for JNK activity for Bcr/Abl
induced transformation in vitro. The conclusions drawn from the data presented
in this section can be summarized as follows:
Both Bcr/AbIP210 and Bcr/Ab1P185 require JNK activity to induce lymphoid
transformation. While JNK1 alone plays a critical role in Bcr/AbIP210
induced pro- B cell growth in vitro (Fig. 7), JNK activity is required to elicit
Bcr/Ab1 P185 stimulated GF- independent proliferation of Baf3 cells (Fig. 9
and Fig. 10). These results suggest that JNK might have a role in eliciting
GF- independent proliferation in primary pro-B cells transformed by
Bcr/Ab1 P185
The depletion of JNK activity does not affect the cell cycle in either
Bcr/AbI P210 or Bcr/Ab1P185 transformed Iymphoblasts (Fig. 7D and Fig. 10),
but it clearly induces apoptosis in Bcr/Ab1P185 cell lines upon IL-3 removal
(Fig. 11). Collectively, these data suggest a potential role of JNK in
mediating a survival signal in Bcr/Abl transformed cells.
. The two Bcr/Abl isoforms have different dependency on JNK activity for
transformation. This could be due to the presence in the Bcr/AbIP210 of the
Dbl domain. I show that this domain can trigger JNK activation in vitro
(Fig. 10). Thus , the presence of the Dbl domain may link the JNK
pathway to the pathogenesis caused by the Bcr/AbIP210 oncogene. In
contrast , Bcr/Ab1 P185 might compensate the lack of the Dbl-activated
pathway through the engagement of alternative pathways. Thus complete
depletion of JNK activity impairs Bcr/Ab1P185 ability to transform cells.
111. 11. In vivo Approach
The in vitro experiments described in the previous section indicated a
potential role for JNK in sustaining survival of Bcr/Abl transformed cells. I
next sought to examine the physiological relevance of the in vitro results
using two mouse models of Bcr/Abl induced disease that would give rise to
either lymphoid or myeloid leukemia. These experiments could not be
performed in a JNK null background since Jnk1-/- Jnk2-
/- 
mice are not viable
and in vivo treatment with the JNK inhibitory drug (SP600125) might induce
secondary toxic effects. Nevertheless, based on the observation that JNK1 is
the predominant isoform in Bcr/Abl transformed lymphoblast (section II I. LA)
and it is critical for Bcr/AbIP210 induced transformation in vitro (section III.I.B) I
used Jnk1-
/- 
cells to examine the role of JNK in Bcr/Abl induced leukemia. In
section II LI LA , I present the results obtained using an in vivo model for
Bcr/Abl induced lymphoid leukemia. These experiments indicated that JNK1
has a role in Bcr/AbIP210 and not Bcr/Ab1P185 induced lymphoid leukemia. In
particular, Bcr/AbIP210 transformed Iymphoblasts were unable to infiltrate
peripheral organs in the absence of JNK1. Additional analysis suggested that
JNK1 might have a role in providing a survival signal in Bcr/AbIP210
transformed Iymphoblasts (section IILlI.B). This signal seemed to be
mediated in part by the upregulation of Bcl2 expression. Based on these
observations I tried to rescue the lymphoid transformation defect caused by
JNK1 deficiency using transgenic mice that overexpress Bcl2 in the B cell
compartment. The results of these experiments are described in section
II LI LB. Finally, since Bcr/AbIP210 is mainly associated with human myeloid
leukemia, I examined the role of JNK1 in Bcr/AbIP210 induced myeloid
leukemia using a mouse model for Bcr/Abl- induced myeloproliferative disease
(section III.II.C).
IILlI.A. Analysis of the effect of JNK1 disruption on Bcr/Abl induced
Iymphoid leukemia
To test the role of JNK1 in transformation of pre- B cells by Bcr/Abl in vivo
I used a method that has been previously described to cause pre-B cell
transformation in mice (Daley et aI. , 1990; Van Etten , 2001 a; Van Etten , 2001 b).
I reconstituted lethally irradiated mice with bone marrow derived from wild-type
and Jnk1-
/- 
donors transduced with retroviral vectors. The effect of Bcr/AbIP210
and Bcr/Ab1P185 expression was examined. Control studies were performed with
the empty vector which expresses GFP from an internal ribosome entry site. The
development of leukemia occurred with an initial expansion of a homogeneous
population of immature blasts evident in the femur sections of mice transplanted
with Bcr/Abl transduced bone marrow , but not vector transduced bone marrow
(Fig. 13A). At the terminal stage of leukemia the bone marrow of these animals
showed increased stromal cells and vascularity with extensive fibrosis (Fig. 13B)
resembling the spent phase typical of myeloproliferative diseases. Mice
transplanted with bone marrow transduced with empty vector (GFP retrovirus)
did not develop leukemia during the period of experimental analysis (100 days)
and normal reconstitution of the bone marrow was observed (Fig. 13A, B). No
marked differences in the histology of femur (Fig. 13B) or the number of proviral
integrations in bone marrow genomic DNA was detected between mice
transplanted with wild-type and Jnk1-
/- 
bone marrow cells by Bcr/Abl in vivo.
Immunophenotyping of bone marrow from mice transplanted with
Bcr/AbIP210 transduced Jnk1-
/- 
marrow revealed the presence of two distinct
populations that express GFP (Fig. 13C). The population with higher GFP
intensity expressed exclusively B-cell markers (B220 and CD19) while the lower
intensity GFP cells expressed myeloid and lymphoid markers (Gr- , CD11 b/Mac-
1, CD19 and B220)(Fig. 13C). Both populations were negative for the erythroid
lineage marker Ter119 and for the T cell surface antigen Thy1. , and the B cell
antigens Sca- , IgA IgG and IgM. This analysis indicated that Bcr/Abl caused
leukemia with both lymphoid and myeloid components. Similar results were
obtained from the analysis of wild-type and Jnk1-
/- 
bone marrow in experiments
using Bcr/AbIP210 and Bcr/Ab1P185 (Fig. 13C and data not shown). I confirmed that
the disease observed was leukemia by secondary transplantation assays.
Together, these data demonstrate that Bcr/AbIP210 and Bcr/Ab1P185 caused a
similar bone marrow disease (mixed lymphoid and myeloid leukemia) in mice
transplanted with wild-type and Jnk1-
/- 
bone marrow (Fig. 13). This conclusion
(\ 80
Fig. 13 JNK 1 is not required for bone marrow disease in 
Bcr/Abl-induced lymphoid leukemia. 
(A) Lethally irradiated mice were reconstituted with
Jnk1-
/- 
bone marrow cells transduced with vector (GFP)
or Bcr/Ablp185 (Bcr/Abl) MSCV retroviruses. Femur sec-
tions (3 weeks post reconstitution) were stained with
hematoxylin and eosin (H&E).
(B) Mice were reconstituted with WT or Jnk1-/-bone 
marrow cells transduced with MSCV retroviruses. Femur .a
sections from animals at the terminal stage of disease 
(Bcr/Ablp185 and Bcr/Ablp210) and from matched con- trois (GFP) were staIned with H&E. 
(C) Bone marrow from pre-moribund mice reconstituted 
with Jnk 1-/- bone marrow cells transduced with control '* 20
(GFP) or Bcr/Ablp185 were examined by flow cytometry(forward scatter (FSC) and GFPfluorescenceintensity) 0 ,
and by analysis of Wright-Giemsa stained cytospin
slides (upper panels). Two populations of GFP-positive
cells with high (blue) and low (red) levels of GFP were detected. These popoulation were examined by flow
cytometry for the surface markers B220 , Mac-1, Gr- 1 and CD19 (lower panels). Cell populations positive for
these cell surface markers(*)were Identified by comparison with unstained cells (dotted lines).
Cells expressing low levels of GFP(red) were positive for B220, Mac- 1 , Gr- 1 and tD19. Similar data were
obtained in experiments with Bcr/Ablp185 and Bcr/Ablp210 and also experiments using WT and Jnkt-/- cells.
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markedly contrasts with the results of in vitro assay that demonstrate an essential
requirement of JNK1 for pre-B cell transformation (Fig.7).
Bcr/Abl- induced leukemia is an invasive disease. Malignant cell
expansion in the bone marrow precedes increased white blood cell number and
the subsequent infiltration of peripheral organs, including the spleen and liver. A
consequence of this malignant infiltration is organomegaly. Thus, mice
reconstituted with wild-type marrow transduced with Bcr/AbIP210 or Bcr/Ab1P185
Jnk1-
/- 
marrow transduced with Bcr/Ab1 P185 showed a marked enlargement of the
spleen (n=28) compared to GFP vector controls (n=22) (Fig. 14A). In contrast,
the spleen mass of animals with Jnk1-
/- 
marrow transduced with Bcr/AbIP210 was
similar to GFP vector control animals (Fig. 14A). These data indicate that JNK1-
deficiency caused a selective defect in splenomegaly caused by Bcr/AbIP210
The absence of splenomegaly suggests that there might be a defect in the
malignant infiltration of peripheral organs of animals transplanted with Jnk1-
bone marrow transduced with Bcr/AbIP210. To test this hypothesis , I performed
histological examination of the spleen and liver. Malignant infiltration in the white
and red pulp of the spleen was classified as follows: Infiltrated , with substantial
infiltration of both the white and red pulp; Partial , with infiltration of either the
white or red pulp; and Minimal , with small foci or no malignant cells. Malignant
infiltration in the liver was classified as follows: Infiltrated, which showed
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Flg. 14 JNK1-deficiency causes reduced infiltration of
peripheral organs by Bcr/Ablp210 transformed lym-
phoblast. (A) Lethally irradiated mice were reconstitut-
ed with WT or Jnk1-1- bone marrow transduced with
vector (GFP) or Bcr/Abl MSCV retroviruses. The
spleens were harvested from pre-moribund Bcr/Abl
mice (p185 and p210) and healthy control mice
(GFP).The mean spleen weight (:lSEM; n=28 for pi8S
and p210; n=22 for GFP) is presented. Statistically
significant differences (p 0001 ; Kruskal-WaHace
test) between WT and Jnkl-I- are ilustrated (*). (B)
Representative spleen (left panels) and liver (right
paneis) sections stained with H&E from Bcr/Abl mice
(pi8S and p210) and vector control mice (GFP) are
ilustrated.
Malignant infiltration in the spleen red pulp(R)and
white pulp(W) was classified as Infiltrated , Partial or
Minimal. Malignant infiltration in the liver was classi-
fied as Infiltrated, Minimal or Normal. The data is
based on the pathology detected in each group of ani-
mals (21-27 animal per group for the spleen and 24-
28 animals per gJOup for the Iiver)(lower panels).
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Fig. 15 JNK1-deficiency increases Bcr/Abr lymphoid disease latency.
(A) Lethally irradiated mice were reconstituted with WT or Jnk1-1- bone
marrow cells transduce with vector (GFP) or Bcr/Abl MSCV retrovirus.
Peripheral white blood cell (WBC) numbers in Bcr/Abl (p1SS and p210)
and vector control (GFP) reconstituted mice were measured. The data
represent the mean count determined in each group (ten mice per group
at day 0). Similar results were obtained!n two independent experiments.(B) Survival of lethally irradiated mice receiving transduced bone marrow
cells (Kap1an-Meier). The survival data are cumulative from three inde-
pendent experiments. There were 28 animals in each Bcr/Abl experimen-
tal group and 22 animals in each control group (WT GFP and Jnk1-
GFP). The prolonged survival of mice reconstituted with Bcr/Abl (p2.
and p1SS) transduced Jnk1-1- bone marrow is statistically significant com-
pared to the survival of mice with WT bone marrow transduced with
Bcr/Abl (tog-rank test p..0002).
perivascular and
sinusoidal infiltration;
Minimal , with small
perivascular foci; and
Normal , with no
malignant cells
detected. The
histological analysis
confirmed that there
was reduced infiltration
of the spleen and liver
(Fig. 14B) of mice
transplanted with
Jnk1-
/- 
marrow
transduced with
Bcr/AbI P210. However
JNK1-deficiency did not
alter the extent of
malignant infiltration caused by Bcr/AbIP185 . These data indicated that JNK1-
deficiency alters the leukemic disease load caused by Bcr/AbIP210 , but not that
caused by Bcr/AbIP185. This altered form of leukemia was characterized by the
proliferation of malignant cells in the bone marrow, but failure of these malignant
cells to efficiently infiltrate peripheral organs.
To examine the cause of the reduced infiltration of peripheral organs by
malignant Jnk1-
/- 
Bcr/AbI P210 cells. I investigated the presence of these cells in
the blood. The number of white blood cells (WBC) in the peripheral blood of
lethally irradiated mice reconstituted with bone marrow transduced with the
empty vector increased gradually with time and was not affected by JNK-
deficiency (Fig. 15A). In contrast, Bcr/Ab1P185 and Bcr/AbIP210 caused a rapid
increase in the number of WBC within 2-3 weeks after reconstitution (Fig. 15A).
A rapid decline in WBC number was observed during the terminal phase of the
disease (Fig. 15A). This decrease correlates with bone marrow failure (Fig.
13B). JNK-deficiency delayed the increase in WBC number caused by
Bcr/Ab1 P185 and by Bcr/AbIP210 (Fig. 15A). These data are consistent with the
hypothesis that JNK1 -deficiency selectively affects Bcr/AbIP210 malignant cells in
the peripheral organs of mice.
Although JNK-deficiency caused changes in the observed leukemia , all
animals reconstituted with Bcr/Abl transduced bone marrow developed leukemia
and died (Fig. 15B). JNK-deficiency caused a statistically significant delay in
disease mortality (log-rank test pc:0.0002). This delay correlates with the delayed
kinetics of WBC accumulation in the peripheral blood (Fig. 15A). The major
cause of death was most likely due to bone marrow failure (Fig. 13B and 15A).
IILlI.B. JNK1 provides a survival signaling in Bcr/AbIP210 lymphoblast
JNK-deficiency was found to cause no apparent defects in the cell cycle of
Bcr/AbI P210 transformed cells in vitro (Fig. 7D). Nevertheless, these cells failed to
accumulate (Fig. 78). This in vitro defect correlates with the observation that
Jnk1-
/- 
Bcr/AbIP210 cells did not accumulate in peripheral organs in vivo (Fig. 14).
One mechanism that could account for the failure to proliferate is increased
apoptosis. Thus , JNK1 may provide a necessary survival signal.
The activation of anti-apoptotic pathways, including the Akt pathway and
the expression of Bcl2-related proteins, is closely linked to the oncogenic
potential of Bcr/Abl. I found similar protein levels of the pro-survival kinase Akt in
wild-type and Jnk1-
/- 
cells but detected a modest reduction in Akt activation in
Jnk1- bone marrow transduced with Bcr/AbIP210. No difference in Akt activation
was observed in Bcr/Ab1P185 transduced cells (Fig. 16A). The anti-apoptotic Bcl2
family member Bcl- is implicated in several hematopoietic malignancies and it
is known that Bcr/Abl increases Bcl- expression , in part by the Stat5 pathway
(see Introduction section LlI.C). However , immunoblot analysis failed to show
any differences in the expression of Bcl- protein or mRNA (Fig. 16C). In
contrast , JNK-deficiency caused marked decrease in Bcl2 (Fig. 16B) and BclW
expression (Fig. 16C). No change in the expression of Bax , Bak or Bad was
detected (Fig. 16C). Decreased expression of Bcl2 and BclW together with a
modest reduction in Akt activity, may therefore contribute to the decreased
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Fig.16 JNK1 deficiency causes decreased expression of Bc12.
(A) Bone marrow from WT and Jnk1.
;' 
and (B) WT and Bcl2transgenic mice was transduced in vitro with Bcr/Abl
retroviruses (p210 and P185). Transformed Iymhoblast were examined by immunoblot (18) analysis with antibodies to
(A) AKT, phospho-Ser473 AKT (AKTCP)). (8) JNK and 8012. (C) Ribonuclease protection assays were carried out to
measure the gene expression of the Bcl2-related family members and glyceraldehyde 3-phosphate dehydrogenase
(GADPH). The mRNA expression profile compared with the GADPH is presented as the mean;tSD (n;3). (D) Bcl2 pro-
moter activity was examined in firefly luclferase reporter assays in Baf3 cells. Transfection effciency was monitored
using a reniformis luciferase reporter plasmid. The ce1ls were cotrasfected with an expression vector encoding the
JNK inhibitor JBD and the Bcl2promoter firefly luciferase reporter plasmid. The data presented represent the mean:tSD
(n=3).
survival of Bcr/AbIP210 transformed Jnk1-
/- 
lymphoblast.
To examine the mechanism of reduced Bcl2 expression caused by JNK-
deficiency, I investigated Bcl2 promoter activity with a luciferase reporter gene
assay. Expression of Bcr/AbIP210 caused increased Bcl2 promoter activity (Fig.
16D) this increase was greatly attenuated by expression of JBD , a dominant
inhibitor of JNK. These results indicate that Bcr/AbIP210 causes a JNK-dependant
increase in Bcl2 promoter activity. The JNK protein may also increase Bcl2
expression by inhibiting the ubiquitin-mediated degradation of Bcl2 (Breitschopf
et aI. , 2000).
The observed decrease in Bcl2 expression caused by JNK-deficiency in
Bcr/Abl P210 transformed cells (Fig. 16B) may be functionally significant. To test
this hypothesis, I examined the effect of transgenic expression of Bcl2 in mice.
Immunoblot analysis demonstrated that the transgene restores the expression of
Bcl2 protein in Jnk1-
/- 
Bcr/AbI P210 cells (Fig. 16B; compare lanes 7 and 8).
Control studies indicated that the expression of JNK2 was unaffected by the Bcl2
transgene , JNK-deficiency, and whether Bcr/AbIP210 or Bcr/Ab1P185 was expressed
(Fig. 16B). Together , these data indicate that JNK1-deficiency causes
decreased Bcl2expression in Bcr/Ab1P21 0 transformed cells and that this decrease
can be compensated by transgenic expression of Bcl2 in vivo.
Bone marrow transplantation assays were performed to examine the
effect of the transgenic expression of Bcl2 on Bcr/Abl induced disease. Lethally
irradiated mice were transplanted with bone marrow isolated from non-transgenic
and Bcl2 transgenic mice. Mice transplanted with bone marrow transduced with
a GFP retrovirus (Vector) did not develop leukemia and histological examination
demonstrated no pathology. These data demonstrated that the level of
transgenic Bcl2 expression was not suffcient to cause proliferative disease
during the period of experimental analysis (100 days). In contrast , all animals
transplanted with bone marrow transduced with retroviruses expressing Bcr/Abl
(p210 or p185) developed disease. No statistically significant difference in
splenomegaly was observed between mice transplanted with WT or Jnk1-
/- 
bone
marrow from Bcl2transgenic animals (Fig. 17A). Histological examination
demonstrated a similar amount of malignant infiltration by WT Bcl2 and Jnk1-
Bcl2 cells caused by Bcr/AbIP210 or Bcr/Ab1 P185 in the liver (Fig. 17B) and spleen.
The extent of infiltration by the transformed Bcl2 transgenic cells was greater
than non -transgenic cells (compare Fig. 14B and 17B). However no significant
difference between WT and Jnk1-
/- 
groups of Bcl2 transgenic cells was detected.
Thus, JNK- deficiency caused no change in liver infiltration by Bcl2 transgenic
Bcr/AbIP210 cells (Fig. 17B). This observation is in marked contrast to the severe
defect in malignant infiltration caused by JNK-deficiency in non-transgenic cells
caused by Bcr/AbIP210 (Figure 14B). Together , these data demonstrated that the
Bcl2 transgene rescues the defect in the infiltration of peripheral organs caused
by JNK-deficiency.
I next examined the white blood cell (WBC) number in the peripheral blood
of mice transplanted with Bcl2 transgenic bone marrow. Compared with non-
transgenic WBC (Fig. 15A), the number of Bcl2 transgenic WBC in the
transplanted mice was larger (Fig. 17C). This is consistent with the anti-
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Fig. 17 Bcl2 restores BcrfAbI disease in Jnk1-1- mice.
(A) Lethally irradiated mice were reconstituted with Bcf2
transgenic bone marrow cells transduced with vector
(GFP) or Bcr/Abl retroviruses. The spleens were har-
vested from pre-moribund Bcr/Abl mice (p185 and p210)
and healthy vector control mice (GFP). The mean
spleen weight (;I SEM; n=9 or 10) is presented. No sta.
tistically significant differences (pod.01; Kruskal-Wallace
test) between WT and Jnk1-1- were detected (' ). (B) His-
topathological analysis of liver (stained with H&E) from
representative mice reconstituted with Bc/2transgenic
bone marrow cells transduced with BcrfAbl (p185 and
p210) or control (GFP) retroviruses (upper panels). The
extent of malignant infilration was evaluated from sec-
tions prepared from 9- 10 animals per group and was
classifed as Infitrated, Minimal and Normal (lower
panel). (C) Peripheral white blood cell numbers (WBC) in
mice reconstiuted with Bc/2 bone marrow transduced
with Bcr/Abl (p185 and p210) and control (GFP)
retroviruses. ihe data represent the mean white blood
cell number in each group (9-10 mice per group at day
0). (D) Survival of lethally irradiated mice transplanted
with transgenic Bcf2bone marrow cells transduced with
Bcr/Abl (p185 and p21 0) and control (GFP) retroviruses
(Kaplan-Meier). There were 9-10 animals per group. No
statistically significant difference between WT and
Jnk1-1- groups was detected (log-rank. test p::.02).
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apoptotic function of Bc12. Time course analysis demonstrated that the delayed
Bcr/Abl stimulated increase in peripheral WBC number caused by JNK-deficiency
(Fig. 15A) was not detected in mice transplanted with Bcl2 transgenic bone
marrow (Fig. 17D). This observation indicated that Bcl2 complements the effect
of JNK-deficiency on Bcr/Abl disease. Indeed, the effect of JNK-deficiency on
delayed disease mortality (Fig. 15B) was not observed in mice transplanted with
Bcl2 transgenic bone marrow transduced with Bcr/Abl (Fig. 17D). These data
provide further confirmation that the restoration of Bc/2 expression in JNK-
deficient cells rescues the Jnk1-
/- 
defect in Bcr/Ablleukemogenesis.
111. I. C. J N K1 is required for Bcr/ Abl P210 Iymphoid leukemia but is
dispensable for the development of myeloid disease.
In humans, the presence Bcr/AbIP210 is principally correlated with the onset
of CML , a myeloproliferative disease. Since the results described in the previous
section were obtained in a "mixed type" leukemia (lymphoid and myeloid), I
sought to investigate the role of JNK1 in Bcr/Abl transformation using an
experimental procedure that would induce the development of a
myeloproliferative disease in the transplanted mice (Ren , 2002; Van Etten
2002). Mice reconstituted with bone marrow transduced with Bcr/AbIP210 using
this new procedure developed leukemia within 15 days. Immunophenotyping of
whole bone marrow from the transplanted animals showed the expansion of a
single population of GFP+ cells that were positive for the myeloid markers CD43
Mac- 1 and Gr- 1 and negative for B220 , CD19 and Thy1.2 (Fig. 18A). These
results confirmed the onset of a myeloproliferative disease. All recipients
1000 10000 . 100
100
100
ro 10
goo
100
u. 100
roo 40 600
F$C
00 1000 I 7. 10 OO 100 100
CD43-PE
100 100
.""
5i 00
'04i
goo
0'*0
#-.
097
10 100 100 moo
Gr1-
10 100 1000 100
Mac1-
Hl 100 100 10000
CD19-
-= 0.
1: 0.4
en 0.
:915
30.
. WT
Jnk1-
Jnk 1-
GFP
Bcr/Abl
Fig. 18 JNK1 is not required lor BcrfAbHnduced myeloproliferative disease.
(A) Bone marrow cells from mice reconstiuted with 5-fluorouracil (5-FU) treated Jnk1-
;' 
bone marrow
transduced with Bcr/Ablp210 retrovirus were examined by flow cytometry. A single GFP-positive pop-
ulation was deteced and examined for the indicated surface markers (8220 , CD-43, Thy1.2, Gr-1,
Mac-1 and CD-19). Cell populations positive for these surface markers (blue lines) were identified by
comparison with unstained cells (red lines). Similar data was obtained in experiments with WT and
Jnkl-l. cells. (8, C) Lethally irradiated mice were reconstituted with 5-FU treated WT or Jnkl-
;' 
bone
marrow transduced with vector (GFP) or Bcr/Ablp210 retroviruses. Spleens and livers were harvested
from all recipients (GFP and Bcr/Abl) 15 days post reconstitution. The mean weight (:tSD; 0=10 for
each group) of these organs is presented.(D) Representative liver sections (stained with H&E) from
Bcr/AblP210 and vector control (GFP) mice are illustrated.
transplanted with bone marrow transduced with Bcr/AbIP210 showed a marked
enlargement of the spleen and liver (n=1 0) compared to GFP vector controls
(n=10) (Fig. 18B). No significant difference in splenomegaly (Fig. 18B) or
hepatomegaly (Fig. 18C) was observed between WT and Jnk1-
/- 
transplanted
animals. Histological examination demonstrated a similar amount of malignant
infiltration by WT and Jnk1-
/- 
cells caused by Bcr/ AblP210 in the liver (Fig. 18D)
and lungs, while GFP vector controls showed no infiltration in these tissues. In
contrast, infiltrated cells were found in the spleen of all recipients reconstituted
with bone marrow transduced with GFP vector control. Due to this background
infilration it was impossible to reliably evaluate the extent of Bcr/AbIP210 induced
malignant infiltration in this organ. However no significant difference in liver and
lung infiltration was detected between the WT and Jnk1-
/- 
groups. Taken
together these results indicate that JNK1 is not required for Bcr/AbIP210 induced
myeloproliferative disease.
IILlI.D. Conclusions
In this section I examined the requirement of JNK1 in Bcr/Abl induced
leukemia. For this purpose, I used two different experimental procedures to
induce either lymphoid or myeloid disease in mice. The results obtained in the
experiments using the mouse model for Bcr/Abl- induced lymphoid leukemia
support the following conclusions:
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JNK1 plays a critical role in Bcr/AbIP210 induced lymphoid leukemia. Mice
reconstituted with Bcr/AbIP210 transformed Jnk1-
/- 
bone marrow cells are
defective in peripheral organ infiltration.
This defect in malignant infiltration might cause the delay in disease
mortality observed in recipients transplanted with Bcr/AbIP210 transduced
Jnk1-
/- 
cells.
Despite the defect in malignant infiltration Jnk1-
/- 
lymphoblast transformed
with Bcr/AbIP210 showed normal proliferation in the bone marrow indicating
that while JNK1 is not required for Bcr/AbIP210 initial transformation event
per se it is critical for the maintenance of the malignant Iymphoblasts.
. The defect in malignant infiltration in the peripheral organs is evident in
transplanted animals receiving Bcr/AbIP210 but not in Bcr/Ab1P185 transduced
Jnk1- bone marrow cells. This observation supports the hypothesis
obtained in our in vitro studies that JNK1 plays a critical role in the
transforming ability of Bcr/AbIP210
Biochemical analysis of Bcr/AbIP210 Jnk1- lymphoblasts showed reduced
expression of several anti-apoptotic factors including Bc12. Indeed , JNK
can mediate Bcr/AbIP210 induced Bcl2 transcriptional upregulation (Fig.
16D). Accordingly, transgenic expression of Bcl2 in the lymphoid
compartment rescues the defect in the malignant infiltration of peripheral
organs and also abolishes the delay in disease mortality (Fig. 17).
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. The fact that Bcl2 efficiently rescues JNK1 defect in Bcr/AbIP210 induced
leukemogenesis suggests that JNK1 is providing a critical survival signal
in Bcr/AbIP210 transformed Iymphoblasts.
The results obtained using the mouse model for Bcr/Abl-nduced myeloid
leukemia suggest that:
JNK1 is dispensable for the development of Bcr/AbIP210 induced
myeloproliferative disease. All recipient mice reconstituted with
bone marrow transduced with Bcr/Abl p210 retrovirus develop
comparable organomegaly (Fig. 18) within the same time frame.
JNK1 is not essential for organ invasion by Bcr/AbIP210 transformed
myeloid cells (Fig. 18). Indeed , all mice reconstituted with bone
marrow transduced with Bcr/AbIP210 show similar extent of malignant
infiltration in the liver (Fig. 18) and lungs.
Taken together these observations suggest that JNK1 has an
essential role in Bcr/Abl induced lymphoid disease while it is
dispensable for development of "myeloid" leukemia.
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111. 111. Ex vivo Approach
The observations obtained with the "lymphoid leukemia" model described
in the previous section indicated that Bcr/AbIP210 transformed Jnk1-
Iymphoblasts were able to proliferate and expand in the bone marrow but are
absent in the blood and failed to invade peripheral organs. The inability of
Bcr/AbIP210 transformed Iymphoblasts to leave the bone marrow
microenvironment was rescued by the ectopic expression of the anti-apoptotic
Bcl2 protein. Taken together these observations suggested that JNK1 is
providing an essential survival signal that enables the Bcr/AblP210 transformed
lymphoid cells to proliferate outside the bone marrow microenvironment. One
critical step that allows transformed lymphoblast to survive in the bloodstream
and to invade peripheral organs is the ability to proliferate in the absence of
growth factors normally provided by the bone marrow. This prompted me to
examine the growth factor dependency of Bcr/Abl transformed lymphoblast
derived from the transplanted mice described in section IILlI.A and B. The
derived "ex vivo" cell lines were cultured in the presence or absence of S17
stromal layers which mimics the bone marrow microenvironment. Under these
conditions I examined Bcr/Abl induced growth factor independent proliferation.
The results of these experiments are illustrated in this section.
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IILlII.A. JNK1 is required for Bcr/AbIP210 induced stromal layer 
independence
Wild-type and Jnk1-
/- 
cells expressing Bcr/Ab1 P185 or Bcr/AbIP210 were
obtained from mice transplanted with non-transgenic and Bcl2-transgenic bone
marrow. Flow cytometry analysis demonstrated that the cells obtained were B-
lymphoblast expressing cell surface B220 , CD19, BP-1 and negative for Gr-
Mac-1/CD11b, Sca- , Ter119, Thy1.2 (Fig. 19A). No significant difference
between wild-type and Jnk1-
/- 
was detected by flow cytometry. Immunoblot
analysis demonstrated that these cells expressed similar levels of total Bcr/Abl
tyrosine phosphorylated Bcr/Abl and JNK2 (Fig. 20D). As expected, JNK1 was
detected in all WT cells, but not in Jnk1-
/- 
cells.
We investigated the proliferation of these cells in the presence and
absence of stroma. DNA synthesis was examined by measurement of the
incorporation of BrdU. There was no marked difference detected between cell
lines with different Jnk1 genotype grown in the presence or absence of stroma
(Fig. 19B). Similar results were obtained for Bcl2 transgenic cells (Fig. 19C).
The incorporation of BrdU was also similar in experiments using cells
transformed with Bcr/AbIP210 and Bcr/Ab1P185 (Fig. 19B and C). These
observations indicated that JNK1- deficiency and transgenic Bcl2 expression did
not alter DNA synthesis by these cells.
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Cell death was examined by flow cytometry using Annexin V and 7-
Aminoactinomycin D (7-AAD) staining. Studies of wild-type Bcr/AbIP210 cells
demonstrated a small increase in cell death in the absence of stroma (Fig. 20A)
but a dramatic increase in the apoptosis of Jnk1-
j- 
Bcr/AbI P210 cells (Annexin V+
AAD-) in the absence of stroma. The markedly increased apoptosis of Jnk1-
Bcr/AbI P210 cells was also detected by TUNEL assays (Fig. 20C). In contrast
JNK-deficiency did not cause increased apoptosis of Bcr/Ab1P185 transformed cells
in the absence of stroma (Fig. 20A). Similarly, no increase in the number of
apoptotic cells (Annexin V+ , 7 AAD-) was detected when Bcl2 transgenic cells
were cultured in the absence at stroma (Fig.20B). Furthermore , the apoptotic
defect caused by JNK1 deficiency in transformed Iymphoblasts was not detected
in studies of B Iymphoblasts derived from normal bone marrow cultured in vitro.
Thus the role of JNK1 in mediating survival seems selectively relevant to
transformed cells.
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III.III.B. Conclusions
The ex vivo data presented in this section demonstrate that:
Disruption of the Jnk1 gene did not affect DNA synthesis in Bcr/AbIP210
transformed Iymphoblasts.
. JNK-deficiency caused markedly increased apoptosis when Bcr/AbIP210
transformed Iymphoblasts were cultured in the absence of stroma.
. The transgenic expression of Bcl2 rescued the increased apoptosis
caused by JNK-deficiency in Bcr/AbIP210 lymphoblast. Thus, the ability of
Bcr/AbIP210 transformed cells to become stromal independent requires
JNK1. This role of JNK1 can be replaced by Bcl2 in vivo (Fig. 17) and 
vitro (Fig. 20).
. Together, these data indicate that JNK1 can promote growth factor
independent survival of transformed B Iymphoblasts. Thus JNK1
contributes to the leukemogenic potential of Bcr/AbIP210 by promoting
survival of Bcr/AbIP210 transformed lymphoblast in the blood and in the
peripheral organs
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CHAPTER IV
DISCUSSION AND FUTURE DIRECTIONS
IV.I. JNK and transformation by Bcr/Abl
In humans, the expression of Bcr/Abl is associated with malignancies that
affect either lymphoid (ALL) or myeloid cells (CML) (see Introduction). For this
reason , in our quest to investigate the potential role of JNK in Bcr/Abl induced
transformation I took advantage of different mouse models that would give rise to
either lymphoid or myeloid leukemia. Interestingly, our data suggest that while
JNK activity is required for the Bcr/Abl induced lymphoid transformation (Fig. 
and 14) it is dispensable for the development of myeloid disease (Fig. 18). This
differential requirement for JNK in transformation involving lymphoid or myeloid
cells could be ascribed to several reasons.
First the relative abundance of the JNK isoforms in either the myeloid or
lymphoid compartment might affect the importance of this signaling pathway in
the overall transformation process triggered by Bcr/Abl. Indeed the Bcr/Abl
oncogene activates redundant pathways leading to overlapping biological
outcomes that collectively induce transformation. The preferential use of a
specific pathway to induce a transforming event (such as growth-factor
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independent proliferation) might be influenced by the presence or absence of the
components of the JNK signaling pathway. Thus cell context may playa role in
the choice of signaling pathways that Bcr/Abl employs to transform cells.
Another reason is that the biological outcome mediated by JNK activation is not
required for the transformation process of myeloid cells. Thus , JNK mediates a
cell specific signal that is needed in lymphoid but not myeloid transformation.
This hypothesis entails that myeloid and lymphoid cells require different
transforming programs mediated by the same oncogene. Further studies are
needed to elucidate the mechanisms underlying this discrepancy in JNK
requirement between Bcr/Abl induced myeloid and lymphoid disease.
Two separate mechanisms are employed by Bcr/Abl to transform cells.
First, Bcr/Abl is an activator of several signal transduction pathways that mediate
mitogenesis (Cortez et aI. , 1997). Second, Bcr/Abl is a potent inhibitor of cell
death (McGahan et aI., 1994). The proliferation and survival functions of Bcr/Abl
can be uncoupled. Expression of Bcr/AblP210with a deletion in the Bcr region
(8176-427) in myeloid cells causes resistance to apoptosis in the absence of
increased proliferation (Cortez et aI. , 1995). These cells fail to form tumors in
nude mice. In contrast, wild-type Bcr/Ab1P210 causes increased proliferation and
does cause tumors in nude mice (Cortez et aI. , 1997). Thus, both proliferation
and inhibition of apoptosis are essential for transformation.
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The anti-apoptotic signaling pathways that are activated by Bcr/Abl include
Akt (Neshat et aI. , 2000; Skorski et aI. , 1997), Stat5 (Gesbert and Griffin, 2000;
Horita et aI. , 2000; Shuai et aI. , 1996) and JNK (this study). The relative roles of
these anti-apoptotic pathways are unclear. Gene disruption studies indicate that
Stat5 is not required for transformation by Bcr/Abl (Sexl et aI. , 2000) but is
required for transformation by other leukemogenic oncogenes, including TEL-
JAK2 (Schwaller et aI. , 2000). The effect of Aktgene disruption on Bcr/ Abl
disease has not been reported, but dominant-negative approaches indicate an
important anti-apoptotic role of the Akt pathway (Skorski et aI. , 1997). Here I
demonstrate that JNK contributes to the survival of Bcr/Abl transformed cells (Fig.
11 and 20). However , JNK does not appear to contribute to mitogenesis
because JNK-deficiency caused no defects in DNA synthesis (Fig. 7D and
19B C) and because JNK-deficiency caused no marked defect in blast expansion
in femur sections of mice transplanted with Bcr/Abl-transduced bone marrow
(Fig. 13).
Three lines of evidence indicate that JNK plays an important role in
Bcr/Abl cell survival. First, JNK-deficiency causes a severely reduced number of
Bcr/Ab1P210 cells in the peripheral organs of leukemic animals in vivo (Fig. 14).
Second, depletion of JNK activity causes apoptosis of Bcr/Abl cells cultured in
the absence of growth factors in vitro (Fig. 11 and 20). Third , expression of the
anti-apoptotic protein Bcl2 can rescue the defects caused by JNK- deficiency 
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vivo and in vitro (Fig. 17 and 20B). The survival defect of cells depleted of JNK
activity appears to be caused by the failure of these cells to proliferate
independently of stroma and stroma-derived cytokines. The growth factor-
dependence observed in vitro (Fig. 20) may account for the inability of Bcr/AbIP210
transformed Jnk1-
/- 
cells to accumulate in the blood and peripheral organs 
vivo, although these cells were able to proliferate in the stromal environment of
the bone marrow. Alternatively, the defect in malignant infiltration could be
attributed to the inability of the Jnk1-
/- 
cells to efficiently migrate and metastasize
peripheral organs.
IV. II. Survival signaling mediated by JNK
The mechanism that accounts for the requirement of JNK1 for stroma-
independent growth of Bcr/Ab1P210 cells is unclear. Here I provide evidence that
JNK1 can regulate Bcl2 expression in Bcr/AblP210 transformed cells and that a
Bcl2 transgene rescues the survival defect of Jnk1 /- Bcr/AbIP210 cells (Fig. 16
and 20). The effect of JNK1 on Bcl2 expression may be mediated , in part, by an
ATF2 responsive element in the promoter (Wilson et aI. , 1996). Indeed
Bcr/Ab1P210 causes increased Bcl2 promoter activity in reporter gene assays (Fig.
16D) and also increases the expression of Bcl2 mRNA and protein (Fig. 16C and
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(Sanchez-Garcia and Martin-Zanca, 1997). Loss of Bcl2 in Bcr/AbIP210
transformed cells contributes to increased apoptosis (Sanchez-Garcia and Grutz
1995). Interestingly, the survival function of Akt is also mediated, in part, by
increased Bcl2 expression in Bcr/AblP210 transformed cells (Pugazhenthi et aI.
2000; Skorski et aI. , 1997). Thus , the JNK1 and Akt pathways may co-operate to
induce expression of Bcl2 and the survival of Bcr/Ab1P21 0 transformed cells.
In previous studies, Bcl- has been implicated as an important mediator
of anti-apoptotic signaling in leukemic cells (Packham et aI. , 1998) and in some
cultured cell lines (e.g. HL60) the expression of Bcl- rather than Bcl2 appears
to be dominant (Amarante-Mendes et aI. , 1998). It is most likely that anti-
apoptotic signaling is mediated , in part, by the combined actions of both Bcl2 and
Bcl- . In primary mouse bone marrow cells, JNK1 is required for the normal
expression of Bc12; no effect of JNK1-deficiency on Bcl- expression was
detected (Fig. 16C).
The acquisition of stromal- independent growth by Bcr/Ab1P210 cells may
require the accumulation of secondary mutations. Increased expression of
cytokines may also contribute to stromal independent growth; recent studies
indicate that while IL-3 and GM-CSF are not required (Li et aI. , 2001 b),
oncostatin-M may contribute to myelo- and Iympho-proliferative disease
(Schwaller et aI. , 2000). Studies of Bcr/AbIP210 in p53-deficient mice demonstrate
that the loss of p53 decreases apoptosis , increases the malignant infiltration of
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peripheral organs , increases stromal- independent proliferation , and decreases
the latency of disease mortality (Honda et aI. , 2000; Skorski et aI. , 1996). A
change in p53 status also correlates with the transition from the chronic to the
acute phase of disease in humans. Thus, it is possible that JNK1 influences the
accumulation of secondary mutations by Bcr/Ab1P210 cells. This represents an
additional mechanism by which JNK1 may contribute to the leukemogenic
potential of Bcr/Abl.
IV. III. Apoptosis and survival signaling
Why does JNK activation mediate survival rather than apoptosis in Bcr/Abl
transformed cells? The decision to survive might result from a high level of
survival signaling mediated by other pathways (e.g. ERK or Akt) that are known
to suppress JNK-mediated apoptosis (Davis, 2000). This appears to be unlikely
because , if true, JNK1-deficiency would not lead to increased apoptosis. There
are two alternative possible mechanisms that could account for the actions of
JNK. First, the decision to survive may be the result of altered gene expression
in the tumor cells and therefore the presence of novel targets of the JNK
signaling pathway. This hypothesis implies that the tumor cells re-program the
respon e to JNK activation. Second, it is possible that it is the duration and
amplitude of JNK activation that is critical for the decision to survive or die (Chen
et aI. , 1996). Although transient expression of Bcr/Ablleads to rapid activation of
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JNK, chronic expression of Bcr/Abl causes a high basal level of JNK activity. It is
therefore possible that the survival function of JNK is mediated by the sustained
basal activity. This hypothesis implies that the loss of high basal JNK activity
would lead to apoptosis. Similarly, increased levels of JNK activation would
cause apoptosis (Lei et aI. , 2002). These two alternative hypotheses (re-
programming and extent/duration of JNK signaling) are not mutually exclusive.
IV.lV. Different JNK requirement between Bcr/AblP210 and
Bcrl AblP185
Several studies have implicated JNK in transformation caused by the
leukemogenic oncogene Bcr/Abl (Burgess et aI. , 1998; Dickens et aI. , 1997;
Raitano et aI. , 1995; Shi et aI. , 2000; Shi et aI. , 1999). The role of JNK in survival
signaling was not anticipated in these studies. In addition , these studies did not
anticipate that Bcr/Ab1P210 and Bcr/Ab1P185 might have different JNK requirements.
Here I demonstrate that while depletion of JNK activity affects growth-factor
independent proliferation in both Bcr/Ab1P185 and Bcr/AbIP210 transformed cells, the
latter cells rely primarily on JNK1 activity. Thus, disruption of Jnk1 gene causes
a selective defect in transformation by Bcr/AbIP210 while it has no effect on
Bcr/Ab1P185 induced leukemia. It is possible that the selective effect of JNK1-
deficiency on Bcr/AbIP210 (which is associated with human chronic myelogenous
leukemia) results from the finding that it is a less potent oncogene than
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Bcr/Ab1P185 (which is associated with human acute lymphoid leukemia)
(McLaughlin et aI. , 1987). Alternatively, the selective defect in Bcr/AbIP210
transformation caused by JNK1-deficiency may reflect a qualitative difference in
function between these Bcr/Abl isoforms (ilaria and Van Etten, 1996; Li et aI.
1999; Quackenbush et aI. , 2000). Bcr/AbIP210 differs from Bcr/Ab1P185 because of
the presence of Cdc24/Dbl and plekstrin homology domains (collectively referred
to as Dbl domain) in the Bcr region of the Bcr/AbIP210 fusion protein. These
domains are found in tandem in many exchange factors for small GTP binding
proteins of the Rho family. Two members of the Rho family, Rac1 and Cdc42
are known to regulate JNK (Coso et aI. , 1995; Minden et aI. , 1995). Indeed, 
show that transient expression of Bcr/AbIP210 Dbl domain can induce JNK
activation (Fig. 12). This observation provides a potential Ras-independent
pathway for JNK activation in Bcr/AbIP210 transformed cells. These Bcr/AbIP210
cells may rely on this privileged pathway for JNK activation in order to achieve
the deregulation of specific cellular processes that contribute to malignant
transformation. Decreased levels of JNK activity might hinder the biological
outcome of this specific pathway leading to a defect in oncogenic transformation.
In contrast , Bcr/Ab1P185 might compensate for the lack of the Dbl-activated
pathway through the engagement of alternative pathways. Nevertheless, in
Bcr/Ab1P185 transformed cells JNK is still activated through the Ras pathway. Thus
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complete depletion of JNK activity impairs the ability of Bcr/Ab1P185 to transform
cells.
FUTURE DIRECTIONS
The findings described in this thesis suggest JNK provides a survival
signal in Bcr/AbIP210 transformed lymphoblast. This signal may be mediated
by transcriptional regulation of key effectors (such as Bcl2 or BcIW) that are
critical for maintenance of the malignant cells. The identification of critical
effectors and the subsequent understanding of how specific gene expression
programs translate into malignant transformation could lead to the
manipulation of JNK signaling for therapeutic benefit. One possible approach
to identify these effectors is the utilization of microarray technology. This
technique allows the analysis of gene transcription in a specific tissue or cell
population. The analysis is achieved by hybridizing total mRNA to an array of
oligonucleotide probes. These probes represent most of the identified ORFs
sequenced in the mouse genome project. Data arrays obtained with different
samples can than be compared using Affymetrix specialized software. The
combination of microarray techniques with genetically modified cells can
provide a powerful tool for a comprehensive analysis of the global changes
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mediated by JNK during transformation by Bcr/Abl. In particular, gene
expression between wild-type and JNK-deficient cells could be compared by
taking advantage of the "ex vivo" lymphoid cell lines that were isolated from
the reconstituted animals. In addition , this analysis could be performed using
different growing conditions to identify potential effectors that mediate JNK-
induced growth factor independent proliferation in Bcr/AbIP210 lymphoblast.
Another novel observation reported in this thesis is the differential
requirement for JNK in myeloid versus lymphoid transformation and between
the two isoforms of the Bcr/Abl oncogene (Bcr/AbIP185 and Bcr/AbIP210). While
JNK1 alone is critical for Bcr/AbIP210 lymphoid but not myeloid transformation
inhibition of both JNK1 and JNK2 activities is required to prevent Bcr/Ab1P185
malignant prolieration. Thus, in order to verify if JNK has a role in myeloid
and Bcr/Ab1P185 induced leukomogenesis it would be essential to use either
Jnk1 Jnk2 deficient mice or a pharmacological inhibitor of these kinases.
Unfortunately, the inactivation of Jnk1Jnk2 genes results in early embryonic
lethaliy and pharmacological inhibitors available for JNK kinases would
probably have high toxicity in vivo. Thus, a "conditional" gene targeting
strategy could be used to circumvent these issues. Conditional gene
targeting refers to a gene modification in the mouse that is restricted to either
certain cell types (tissue specific) or to a specific stage within development
(temporally specific) or both. Compared to "conventional" gene targeting, the
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conditional strategy will test the function of a widely expressed gene in a
particular tissue without being influenced by gene loss in adjacent tissues, as
the rest of the embryo is genetically wild-type. There are two systems to
achieve conditional gene inactivation in mice: the cre- loxP system (Lakso et
aI. , 1992; Orban et aI. , 1992; Sauer, 1998) and the Flp recombinase from
Saccharomyces cerevisiae (Dymecki , 1996). Both of these systems are
based on the use of site-specific recombinases, which allow targeted excision
of specific genes flanked by recognition sites (such as loxP sites). Thus, the
gene of choice can be universally targeted with the loxP sites throughout the
animal and tissue specific excision can be achieved by crossing these
animals with transgenic mice, which ectopically express the heterologous
recombinase in specific tissues. By using this approach it would be possible
to obtain viable mice which are Jnk null in the lymphoid or myeloid
compartment. These mice can be used as donors in reconstitution assays
designed to investigate the role of JNK both in Bcr/Ab1P185 induced
transformation and in Bcr/Abl induced myeloproliferative disease.
;r,
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